Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Oncology›Condition·Updated Jul 11, 2026·v1

Breast Cancer

Breast cancer is a heterogeneous disease best managed by a multidisciplinary team using stage- and subtype-specific approaches. Neoadjuvant therapy provides response-guided care, and genomic assays refine chemotherapy decisions. Targeted therapies have improved outcomes for HER2+, HR+, and triple-negative subtypes. Early detection remains critical, but global disparities in access to care persist.

High Evidence1000 references·3,177 words·13 min read·v1
breast canceroncologymammographyHER2triple-negativeBRCAgenomic testingCDK4/6 inhibitortrastuzumabneoadjuvant therapy

Quick Reference

RxDrug of choiceEarly HR+/HER2-: letrozole 2.5 mg/day (postmenopausal) or tamoxifen 20 mg/day + OFS (premenopausal). Metastatic HR+/HER2-: ribociclib 600 mg/day + letrozole 2.5 mg/day. HER2+: trastuzumab 8 mg/kg load then 6 mg/kg q3w + pertuzumab 840 mg load then 420 mg q3w + docetaxel 75 mg/m2 q3w. TNBC: pembrolizumab 200 mg q3w + paclitaxel 80 mg/m2 weekly + carboplatin AUC 1.5 weekly (neoadjuvant).
AltAlternativesHR+/HER2-: palbociclib 125 mg/day 3/1, abemaciclib 150 mg BID, fulvestrant 500 mg IM days 1,15,29 then monthly, exemestane 25 mg/day, anastrozole 1 mg/day, elacestrant 345 mg/day (ESR1-mutated). HER2+: T-DM1 3.6 mg/kg q3w, T-DXd 5.4 mg/kg q3w, tucatinib 300 mg BID, lapatinib 1250 mg/day, neratinib 240 mg/day. TNBC: sacituzumab govitecan 10 mg/kg days 1+8 q3w, capecitabine 1250 mg/m2 BID days 1-14 q3w, olaparib 300 mg BID, talazoparib 1 mg/day.
⊘AvoidTrastuzumab in pregnancy (category D - oligohydramnios); non-dihydropyridine CCBs (diltiazem, verapamil) with HF; live vaccines during chemotherapy; tamoxifen in patients with history of thromboembolic events; anthracyclines in patients with EF <50% or prior anthracycline exposure.
DxTest of choiceCore needle biopsy with IHC for ER/PR/HER2/Ki-67, plus multigene assay (Oncotype DX) for HR+/HER2- node-negative breast cancer (NCCN Category 1).
ScKey scoreOncotype DX Recurrence Score (RS): low ≤10, intermediate 11-25, high ≥26. TAILORx: RS ≤10 → endocrine therapy alone; RS ≥26 → chemo + endocrine.
→When to referGenetic counseling for all patients ≤65 years old, all TNBC, all male breast cancer, or family history of BRCA-related cancers; fertility preservation specialist before starting systemic therapy; radiation oncology for RT planning; medical oncology for systemic therapy; palliative care for symptom management in advanced disease.
Breast cancer management is driven by molecular subtype and stage, with neoadjuvant therapy enabling response-guided escalation/de-escalation. Genomic assays spare chemotherapy in low-risk HR+ disease, and targeted therapies (HER2 blockade, CDK4/6 inhibitors, PARP inhibitors, immune checkpoint inhibitors) have transformed outcomes. Early detection remains critical, but global disparities in access to care persist.
Breast cancer is the most common malignancy in women worldwide, with incidence rising globally but mortality declining in high-income countries due to screening and multimodal therapy. Management is driven by molecular subtype (HR, HER2, genomic risk) and stage, integrating surgery, radiation, and systemic therapy. This concise reference distills key clinical facts, drug doses, critical thresholds, and evidence-based pearls for bedside use.

Overview and Recommendations

Background

  • •Breast cancer is a malignant neoplasm arising from the terminal ductal-lobular unit, with an estimated 2.3 million new cases and 685,000 deaths globally in 2020. It is the most frequently diagnosed cancer among women worldwide and the leading cause of cancer-related death in women, with geographic variation: incidence highest in high-income countries, mortality highest in low- and middle-income countries (LMICs) due to late-stage presentation and limited treatment access, 5-year survival in LMICs is <40% versus >90% in high-income settings.
  • •Molecular subtypes defined by gene expression, luminal A (ER+/HER2-, low Ki-67, best prognosis), luminal B (ER+/HER2±, higher Ki-67), HER2-enriched (HER2+, aggressive but targetable), and basal-like (triple-negative, poor prognosis), guide treatment and prognosis. Triple-negative breast cancer (TNBC) is three times more common in women of African descent and premenopausal women, and accounts for 10-20% of all breast cancers.
  • •Genetic predisposition accounts for 5-10% of cases, with high-penetrance genes: BRCA1 (57% lifetime risk by age 70), BRCA2 (49%), PALB2 (35%), TP53 (80-90%), PTEN (>50%), and CDH1 (42% for lobular breast cancer). Moderate-penetrance genes include CHEK2 (OR 2.4), ATM (OR 2.16), and BARD1/RAD51C/RAD51D, which are associated with TNBC risk. ASCO-SSO guidelines recommend BRCA1/2 testing for all newly diagnosed patients ≤65 years and for all TNBC at any age.
  • •Risk factors: age, mammographic breast density (4- to 6-fold risk increase), obesity (35-40% higher risk of recurrence and death), alcohol (dose-dependent), hormonal contraceptives (HR 1.24 for current use), and PM2.5 air pollution (HR 1.28 per 10 μg/m³). Protective factors include breastfeeding (pOR 0.77-0.79), physical activity ≥6 h/week (HR 0.72), and parity (reduces luminal risk by 25%). The MAP.3 trial showed that exemestane reduces invasive breast cancer by 65% in high-risk postmenopausal women.
  • •The paradigm shift in management over the past three decades: from radical mastectomy to breast-conserving surgery with sentinel lymph node biopsy, and from empirical chemotherapy to genomically guided therapy (TAILORx, MINDACT) and targeted therapy (HER2 blockade, CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors). The residual cancer burden (RCB) after neoadjuvant therapy is a powerful prognostic tool, with 10-year relapse-free survival ranging from 86% (RCB-0) to 23% (RCB-III) in TNBC.

Evaluation

  • •Suspect breast cancer in any patient with a painless, firm, irregular breast lump; skin dimpling, erythema, ulceration, or nipple retraction; spontaneous bloody nipple discharge; or axillary adenopathy. Inflammatory breast cancer (IBC) presents with diffuse breast enlargement, erythema, warmth, and peau d'orange without a discrete mass, urgent biopsy is required as it is often mistaken for mastitis.
  • •Evaluate with diagnostic mammography (preferably with tomosynthesis) and ultrasound. For high-risk patients (BRCA1/2, lifetime risk >20%, prior chest radiation), annual breast MRI starting at age 30 (or 25 for BRCA1/2) reduces breast cancer mortality by 80% (HR 0.20; 95% CI 0.10-0.43). In dense breasts, MRI detects 2.5 vs 5.0 interval cancers per 1000 screenings (DENSE trial).
  • •Obtain core needle biopsy (CNB) as the preferred method for tissue diagnosis; place in 10% neutral buffered formalin with cold ischemia time <1 hour. Fine-needle aspiration (FNA) is inadequate for distinguishing invasive from in situ disease. For suspicious calcifications, stereotactic or vacuum-assisted biopsy is required.
  • •Assess histologic type (e.g., invasive ductal NST, invasive lobular, tubular, mucinous, medullary) and Nottingham grade (tubule formation, nuclear pleomorphism, mitotic count). Invasive lobular carcinoma (ILC) shows discohesive single-file cells and requires E-cadherin IHC for confirmation; it often presents as subtle thickening rather than a discrete mass.
  • •Determine ER/PR status by IHC: ER-positive if ≥1% nuclear staining; report 1-10% as ER Low Positive with a comment on limited data for endocrine therapy benefit. HER2 testing by IHC with reflex ISH for IHC 2+: positive if IHC 3+ (uniform intense membrane staining in >10% of cells) or ERBB2/CEP17 ratio ≥2.0 with average copy number ≥4.0 signals/cell. HER2-low is defined as IHC 1+ or IHC 2+/ISH-negative and is now targetable with deruxtecan (T-DXd).
  • •Order Ki-67 proliferation index (prognostic, though lack of standardization limits standalone use; Ki-67 ≥20% is commonly considered high). Consider multigene assay: Oncotype DX (21-gene recurrence score) for node-negative HR+/HER2- disease, TAILORx showed RS ≤10: endocrine therapy alone, RS 11-25: no chemo benefit, RS 26-100: chemo improves outcomes. MammaPrint (70-gene) is an alternative for clinical high-risk/genomic low-risk patients.
  • •Stage with AJCC 8th edition, integrating anatomical TNM and prognostic factors (grade, ER/PR, HER2, genomic assays). For clinical stage IIA-IIIC, consider 18F-FDG PET/CT as an alternative to CT chest/abdomen/pelvis + bone scan; it identifies distant metastases in 14% and upstages nodal disease in 37%, with lower radiation dose (14 mSv vs 21 mSv) and shorter time to treatment initiation.
  • •In patients with metastatic disease, rebiopsy for receptor discordance (up to 40% of cases for PR and HER2). Consider liquid biopsy (ctDNA) to detect ESR1 mutations (guides elacestrant use), PIK3CA mutations (alpelisib), and for monitoring treatment response. Post-surgical ctDNA detection predicts metastatic recurrence with a lead time of 8.9-10.7 months (sensitivity 89-96%).
  • •For high-risk patients (HER2+ or TNBC), consider screening brain MRI at baseline and at progression; occult brain metastases are found in 9.8% at baseline, rising to 19.6% by third-line therapy. In patients with HER2+ brain metastases, tucatinib combined with trastuzumab and capecitabine improves overall survival (HER2CLIMB: median OS 21.6 vs 12.5 months).

Management

  • •For early-stage breast cancer, decide between neoadjuvant and adjuvant systemic therapy. Neoadjuvant is preferred for inflammatory breast cancer, locally advanced disease, and when downstaging enables breast-conserving surgery. Achieving pathologic complete response (pCR) is strongly prognostic (HR 0.31 for event-free survival across subtypes), especially in TNBC (HR 0.18) and HER2+ disease (HR 0.32).
  • •For HR+/HER2- disease: initiate endocrine therapy. For premenopausal women, tamoxifen 20 mg/day ± ovarian function suppression (OFS) with exemestane 25 mg/day; SOFT trial showed 12-year DFS 79.0% with OFS+exemestane vs 71.9% with tamoxifen alone (HR 0.79). For postmenopausal women, aromatase inhibitors (letrozole 2.5 mg/day, anastrozole 1 mg/day, exemestane 25 mg/day) are standard.
  • •For high-risk HR+/HER2- disease (node-positive, grade 3, high Ki-67, or genomic high risk), add a CDK4/6 inhibitor: abemaciclib 150 mg BID for 2 years (monarchE: 7-year OS 86.8% vs 85.0%, HR 0.842) or ribociclib 400 mg/day for 3 years (NATALEE: 4-year iDFS 88.5% vs 83.6%, HR 0.72). These are recommended for patients with stage II-III disease with additional risk factors.
  • •For HER2+ disease: use dual HER2 blockade with trastuzumab (8 mg/kg loading then 6 mg/kg q3w) and pertuzumab (840 mg loading then 420 mg q3w) plus chemotherapy. For neoadjuvant therapy, ddAC (doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 q3w) followed by THP (paclitaxel 80 mg/m2 weekly + trastuzumab + pertuzumab) is standard. For residual disease after neoadjuvant therapy, switch to T-DM1 3.6 mg/kg q3w for 14 cycles (KATHERINE: 3-year iDFS 88.3% vs 77.0%, HR 0.50).
  • •For metastatic HER2+ disease: first-line T-DXd 5.4 mg/kg q3w + trastuzumab + pertuzumab (DESTINY-Breast03: 12-month PFS 75.8% vs 34.1%, HR 0.28). For brain metastases, add tucatinib 300 mg BID (HER2CLIMB: OS 21.6 vs 12.5 months, HR 0.60). For HER2-low metastatic disease, T-DXd improves PFS vs chemotherapy (DESTINY-Breast04: 13.2 vs 8.1 months, HR 0.62).
  • •For triple-negative breast cancer (stage II-III): neoadjuvant pembrolizumab 200 mg q3w + carboplatin AUC 1.5 weekly + paclitaxel 80 mg/m2 weekly for 12 weeks, followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 q3w for 4 cycles, then adjuvant pembrolizumab 200 mg q3w for 9 cycles (KEYNOTE-522: pCR 64.8% vs 51.2%, 5-year OS 86.6% vs 81.7%). For residual disease after neoadjuvant chemotherapy, give adjuvant capecitabine 1250 mg/m2 BID days 1-14 q3w for 6 cycles (CREATE-X: 5-year DFS 74.1% vs 67.6%, HR 0.70).
  • •For metastatic TNBC: first-line pembrolizumab + chemotherapy (for PD-L1 CPS ≥10) or atezolizumab + nab-paclitaxel (for PD-L1 IC ≥1%). Second-line: sacituzumab govitecan 10 mg/kg on days 1 and 8 of 21-day cycles (ASCENT: OS 12.1 vs 6.7 months, HR 0.48). For BRCA1/2-mutated metastatic TNBC, consider PARP inhibitors: olaparib 300 mg BID or talazoparib 1 mg/day (OlympiAD: PFS 7.0 vs 4.2 months, HR 0.58).
  • •Locoregional management: breast-conserving surgery (lumpectomy) with whole-breast irradiation is standard. For women ≥70 years with stage I, ER+ disease, omission of radiotherapy after lumpectomy is an option (CALGB 9343: 10-year LR 10% vs 2%, no OS difference). Axillary management: sentinel lymph node biopsy (SLNB) is standard for clinically node-negative. For cN1 converting to ypN0 after neoadjuvant therapy, regional nodal irradiation does not improve outcomes (NSABP B-51: HR 0.88, p=0.51). Omission of axillary surgery can be considered for cT1-T2 N0 with negative axillary ultrasound (SOUND trial).
  • •Monitoring: post-treatment surveillance includes clinical exam every 3-6 months for 3 years, then every 6-12 months, and annual mammography. Routine imaging for asymptomatic patients is not recommended except for annual mammography. Adjuvant bisphosphonates (zoledronic acid 4 mg IV q6 months for 3-5 years) reduce bone recurrence in postmenopausal patients. For patients on aromatase inhibitors, monitor bone density and consider calcium/vitamin D supplementation.
  • •Avoid: non-dihydropyridine CCBs (diltiazem, verapamil) in patients with heart failure; trastuzumab during pregnancy (causes oligohydramnios); radiotherapy during the first trimester; tamoxifen in patients with history of thromboembolic events. Do not use anthracyclines in patients with cardiac risk factors if alternative regimen is available. Refer to genetic counseling for all patients ≤65 years, TNBC at any age, or family history suggestive of hereditary syndrome. Refer to fertility preservation specialist before starting systemic therapy.

Board Review — High Yield

  • •Triple-negative breast cancer - ER-/PR-/HER2-, associated with BRCA1 mutations, peak recurrence within 3 years. KEYNOTE-522: neoadjuvant pembrolizumab + chemotherapy improves pCR (64.8% vs 51.2%) and 5-year OS (86.6% vs 81.7%).
  • •Oncotype DX - 21-gene recurrence score (RS) for HR+/HER2- node-negative breast cancer. TAILORx: RS ≤10 → endocrine therapy alone; RS ≥26 → chemo + endocrine; RS 11-25 → no chemo benefit (for age >50) or consider chemo for age ≤50 with RS 16-25.
  • •HER2-targeted therapy - Trastuzumab + pertuzumab + taxane for HER2+ disease (APHINITY: 8-year iDFS 86.1% vs 81.2% for node-positive). T-DM1 for residual disease after neoadjuvant therapy (KATHERINE: HR 0.50). T-DXd superior to T-DM1 in metastatic setting (DESTINY-Breast03: HR 0.28).
  • •CDK4/6 inhibitors - Ribociclib, palbociclib, abemaciclib improve PFS in metastatic HR+/HER2-. Adjuvant: abemaciclib (monarchE) for high-risk node-positive, ribociclib (NATALEE) for stage II-III with risk factors.
  • •Inflammatory breast cancer - Clinical triad: erythema, edema (peau d'orange), warmth without discrete mass. Requires urgent biopsy and neoadjuvant chemotherapy. Not a histologic diagnosis but a clinical syndrome.
  • •BRCA1/2 testing - Offer to all patients ≤65 years, all TNBC, all male breast cancer, and family history of BRCA-related cancers. PARP inhibitors (olaparib, talazoparib) effective in adjuvant (OlympiA: HR 0.68 for OS) and metastatic settings.
  • •Residual cancer burden (RCB) - After neoadjuvant chemotherapy, RCB index predicts prognosis. 10-year relapse-free survival: 86% (RCB-0) to 23% (RCB-III) in TNBC. Guides adjuvant therapy: capecitabine for TNBC, T-DM1 for HER2+.
  • •Sentinel lymph node biopsy omission - Can be omitted in cT1-T2 N0 with negative axillary ultrasound (SOUND trial: noninferior 5-year iDFS). Also in select postmenopausal women with small HR+/HER2- tumors (INSEMA trial).
  • •Omission of radiotherapy in elderly - Women ≥70 with stage I, ER+ breast cancer: tamoxifen alone is an option (CALGB 9343: 10-year LR 10% vs 2%, no OS difference). PRIME II: 5-year LR 4.1% without RT vs 1.3% with RT.
  • •Pregnancy-associated breast cancer - Worse prognosis (HR 1.44 for death). Chemotherapy safe in 2nd/3rd trimester; trastuzumab contraindicated (oligohydramnios). Delay RT and endocrine therapy until postpartum. POSITIVE trial: temporary interruption of endocrine therapy to attempt pregnancy did not increase short-term relapse risk.

Deep Dive — Evidence Details

References

  1. [1]

    Turnbull C, Achatz MI, Balmaña J et al.. “Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40523834 ↗

    L1GUIDELINECited in: Definition and Epidemiology, Genetics and Hereditary Predisposition
  2. [2]

    Chen CS, Zirpoli G, Barlow WE et al.. “Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37935109 ↗

    L2RCTCited in: Definition and Epidemiology
  3. [3]

    Chumsri S, Pai T, Ma Y et al.. “Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39191270 ↗

    L2RCTCited in: Definition and Epidemiology
  4. [4]

    Biganzoli L, Battisti NML, Wildiers H et al.. “Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).” The Lancet. Oncology (2021). PMID: 34000244 ↗

    L1GUIDELINECited in: Definition and Epidemiology, Risk Factors and Prevention
  5. [5]

    Smith SG, Sestak I, Forster A et al.. “Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26646754 ↗

    L2SR_OBSCited in: Definition and Epidemiology
  6. [6]

    Gianni L, Huang CS, Egle D et al.. “Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35182721 ↗

    L1RCTCited in: Definition and Epidemiology
  7. [7]

    Mamounas EP, Untch M, Mano MS et al.. “Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 33932503 ↗

    L2RCTCited in: Definition and Epidemiology
  8. [8]

    Harbeck N, Fasching PA, Wuerstlein R et al.. “Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37201751 ↗

    L1RCTCited in: Definition and Epidemiology
  9. [9]

    Rafn BS, Christensen J, Larsen A et al.. “Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35077194 ↗

    L2SR_OBSCited in: Definition and Epidemiology
  10. [10]

    Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A et al.. “Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36917758 ↗

    L1RCTCited in: Definition and Epidemiology
  11. [11]

    Meattini I, Marrazzo L, Saieva C et al.. “Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32840419 ↗

    L1RCTCited in: Definition and Epidemiology, Special Populations
  12. [12]

    Bartels SAL, Donker M, Poncet C et al.. “Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36383926 ↗

    L1RCTCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis
  13. [13]

    Sanft T, Harrigan M, McGowan C et al.. “Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37656930 ↗

    L1RCTCited in: Definition and Epidemiology, Clinical Presentation
  14. [14]

    McCormick B, Winter K, Hudis C et al.. “RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25605856 ↗

    L1RCTCited in: Definition and Epidemiology, Clinical Presentation, Prognosis and Prognostic Factors
  15. [15]

    DeCensi A, Puntoni M, Guerrieri-Gonzaga A et al.. “Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30973790 ↗

    L1RCTCited in: Definition and Epidemiology
  16. [16]

    Saura C, Oliveira M, Feng YH et al.. “Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32678716 ↗

    L1RCTCited in: Definition and Epidemiology
  17. [17]

    Kang D, Cho J, Zhao D et al.. “Scalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38843479 ↗

    L1RCTCited in: Definition and Epidemiology
  18. [18]

    Paramanandam VS, Dylke E, Clark GM et al.. “Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer-Related Lymphedema: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35108031 ↗

    L1RCTCited in: Definition and Epidemiology
  19. [19]

    Badwe RA, Parmar V, Nair N et al.. “Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37023374 ↗

    L1RCTCited in: Definition and Epidemiology, Prognosis and Prognostic Factors
  20. [20]

    Swain SM, Ewer MS, Viale G et al.. “Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29253081 ↗

    L4TRIAL_NONRANDOMCited in: Definition and Epidemiology
  21. [21]

    Kerr AJ, Dodwell D, McGale P et al.. “Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality.” Cancer treatment reviews (2022). PMID: 35367784 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Management Overview
  22. [22]

    Hua M, Xiong F, Chong S et al.. “Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation.” Cancer treatment reviews (2024). PMID: 39278067 ↗

    L2SR_OBSCited in: Definition and Epidemiology
  23. [23]

    Santoni M, Guerra F, Conti A et al.. “Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.” Cancer treatment reviews (2017). PMID: 28818671 ↗

    L1SR_OBSCited in: Definition and Epidemiology
  24. [24]

    Soares LR, Vilbert M, Rosa VDL et al.. “Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.” ESMO open (2023). PMID: 37481956 ↗

    L2SR_OBSCited in: Definition and Epidemiology
  25. [25]

    Caparica R, Bruzzone M, Agostinetto E et al.. “Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis.” ESMO open (2021). PMID: 33639601 ↗

    L2SR_OBSCited in: Definition and Epidemiology
  26. [26]

    DiSipio T, Rye S, Newman B et al.. “Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis.” The Lancet. Oncology (2013). PMID: 23540561 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  27. [27]

    . “Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.” The Lancet. Oncology (2017). PMID: 29242041 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Staging, Management Overview, Prognosis and Prognostic Factors
  28. [28]

    Paap E, Verbeek ALM, Puliti D et al.. “Breast cancer screening case-control study design: impact on breast cancer mortality.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20924073 ↗

    L5SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention
  29. [29]

    Klepin H, Mohile S, Hurria A. “Geriatric assessment in older patients with breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19200420 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  30. [30]

    Helvie MA, Bevers TB. “Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30442738 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  31. [31]

    Chlebowski RT, Aragaki AK, Anderson GL. “Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26150583 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  32. [32]

    Jacob S, Mayer EL, Kacik N et al.. “TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.” ESMO open (2026). PMID: 41812623 ↗

    L1RCTCited in: Definition and Epidemiology, History and Evolution of Treatment, Prognosis and Prognostic Factors
  33. [33]

    de Azambuja E, Piccart-Gebhart M, Fielding S et al.. “Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].” ESMO open (2024). PMID: 39418883 ↗

    L1RCTCited in: Definition and Epidemiology, History and Evolution of Treatment, Prognosis and Prognostic Factors
  34. [34]

    Wang SL, Fang H, Song YW et al.. “Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.” The Lancet. Oncology (2019). PMID: 30711522 ↗

    L1RCTCited in: Definition and Epidemiology
  35. [35]

    Poortmans PM, Weltens C, Fortpied C et al.. “Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.” The Lancet. Oncology (2020). PMID: 33152277 ↗

    L1RCTCited in: Definition and Epidemiology, Imaging, Staging
  36. [36]

    Bartelink H, Maingon P, Poortmans P et al.. “Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.” The Lancet. Oncology (2014). PMID: 25500422 ↗

    L1RCTCited in: Definition and Epidemiology, Staging
  37. [37]

    Schmid P, Cortes J, Pusztai L et al.. “Pembrolizumab for Early Triple-Negative Breast Cancer.” The New England journal of medicine (2020). PMID: 32101663 ↗

    L1RCTCited in: Definition and Epidemiology, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  38. [38]

    Turner NC, Im SA, Saura C et al.. “Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.” The New England journal of medicine (2024). PMID: 39476340 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  39. [39]

    Cortés J, Kim SB, Chung WP et al.. “Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.” The New England journal of medicine (2022). PMID: 35320644 ↗

    L1RCTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  40. [40]

    Jhaveri KL, Neven P, Casalnuovo ML et al.. “Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.” The New England journal of medicine (2024). PMID: 39660834 ↗

    L1RCTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  41. [41]

    Tolaney SM, Jiang Z, Zhang Q et al.. “Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.” The New England journal of medicine (2025). PMID: 41160818 ↗

    L1RCTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  42. [42]

    Jhaveri KL, Im SA, Saura C et al.. “Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.” The New England journal of medicine (2025). PMID: 40454641 ↗

    L1RCTCited in: Definition and Epidemiology
  43. [43]

    Manson JE, Cook NR, Lee IM et al.. “Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.” The New England journal of medicine (2018). PMID: 30415629 ↗

    L1RCTCited in: Definition and Epidemiology
  44. [44]

    Cortés J, Punie K, Barrios C et al.. “Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.” The New England journal of medicine (2025). PMID: 41124233 ↗

    L1RCTCited in: Definition and Epidemiology, Clinical Presentation
  45. [45]

    Tolaney SM, de Azambuja E, Kalinsky K et al.. “Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.” The New England journal of medicine (2026). PMID: 41564397 ↗

    L1RCTCited in: Definition and Epidemiology
  46. [46]

    Kunkler IH, Williams LJ, Jack WJL et al.. “Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer.” The New England journal of medicine (2023). PMID: 36791159 ↗

    L1RCTCited in: Definition and Epidemiology, Staging
  47. [47]

    Bakker MF, de Lange SV, Pijnappel RM et al.. “Supplemental MRI Screening for Women with Extremely Dense Breast Tissue.” The New England journal of medicine (2019). PMID: 31774954 ↗

    L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Imaging
  48. [48]

    Villacampa G, Navarro V, Matikas A et al.. “Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.” JAMA oncology (2024). PMID: 39207778 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Management Overview
  49. [49]

    Spring LM, Gupta A, Reynolds KL et al.. “Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.” JAMA oncology (2016). PMID: 27367583 ↗

    L1SR_OBSCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors
  50. [50]

    Michel LL, Schwarz D, Romar P et al.. “Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy: The POLAR Randomized Clinical Trial.” JAMA oncology (2025). PMID: 40048176 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  51. [51]

    Fasching PA, Stroyakovskiy D, Yardley DA et al.. “Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.” JAMA oncology (2025). PMID: 40996773 ↗

    L1RCTCited in: Definition and Epidemiology, Imaging, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  52. [52]

    Partridge AH, Niman SM, Ruggeri M et al.. “Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.” The New England journal of medicine (2023). PMID: 37133584 ↗

    L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Clinical Presentation
  53. [53]

    . “Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.” The Lancet. Oncology (2022). PMID: 35123662 ↗

    L1SR_OBSCited in: Definition and Epidemiology
  54. [54]

    . “Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.” The Lancet. Oncology (2021). PMID: 34339645 ↗

    L1SR_OBSCited in: Definition and Epidemiology
  55. [55]

    Bilancia D, Rosati G, Dinota A et al.. “Lapatinib in breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591827 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  56. [56]

    Boyle P. “Triple-negative breast cancer: epidemiological considerations and recommendations.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23012306 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  57. [57]

    Autier P, Boniol M, Middleton R et al.. “Advanced breast cancer incidence following population-based mammographic screening.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21252058 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Staging
  58. [58]

    Bines J, Earl H, Buzaid AC et al.. “Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24625452 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  59. [59]

    Vasan N, Toska E, Scaltriti M. “Overview of the relevance of PI3K pathway in HR-positive breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31859348 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  60. [60]

    Arthur DW, Winter KA, Kuerer HM et al.. “Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial.” JAMA oncology (2020). PMID: 31750868 ↗

    L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Management Overview
  61. [61]

    Zhong J, Wu L, Song Z et al.. “TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.” Cancer cell (2025). PMID: 41135519 ↗

    L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Special Populations
  62. [62]

    Johansson H, Macis D, Oliva M et al.. “Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40293268 ↗

    L1RCTCited in: Definition and Epidemiology
  63. [63]

    Nozawa K, Iwata H, Mukohara T et al.. “Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study.” ESMO open (2025). PMID: 40714515 ↗

    L2COHORTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  64. [64]

    Jourdain H, Di Meglio A, Mansouri I et al.. “Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study.” ESMO open (2024). PMID: 39662227 ↗

    L3COHORTCited in: Definition and Epidemiology, History and Evolution of Treatment, Prognosis and Prognostic Factors
  65. [65]

    de Andrade KC, Khincha PP, Hatton JN et al.. “Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.” The Lancet. Oncology (2021). PMID: 34780712 ↗

    L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition, Clinical Presentation
  66. [66]

    de Haan J, Verheecke M, Van Calsteren K et al.. “Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients.” The Lancet. Oncology (2018). PMID: 29395867 ↗

    L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  67. [67]

    Kirkham AA, Jerzak KJ. “Prevalence of Breast Cancer Survivors Among Canadian Women.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36075384 ↗

    L2OTHERCited in: Definition and Epidemiology
  68. [68]

    Park C, Liu YS, Kenawy AS et al.. “Cardiovascular Adverse Events and Associated Costs of CDK4/6 Inhibitors in Patients With Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40250478 ↗

    L3OTHERCited in: Definition and Epidemiology
  69. [69]

    Koroukian SM, Dong W, Albert JM et al.. “Treatment Patterns and Survival Outcomes in Patients With Breast Cancer on Medicaid, Pre- and Post-Expansion.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38498974 ↗

    L3OTHERCited in: Definition and Epidemiology
  70. [70]

    Niu C, Zhang J, Singh H et al.. “Impact of Concomitant Proton Pump Inhibitor Use on the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancer Types.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41101342 ↗

    L3OTHERCited in: Definition and Epidemiology
  71. [71]

    Nelson RA, Soto-Perez-de-Celis E, Chlebowski RT et al.. “Predicting All-Cause Mortality in Women With and Without Breast Cancer Using the Schonberg Index: A Women's Health Initiative Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37308127 ↗

    L2OTHERCited in: Definition and Epidemiology
  72. [72]

    Chahoud J, Semaan A, Rieber A. “Wealth, Health Expenditure, and Cancer: A National Perspective.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27496113 ↗

    L2OTHERCited in: Definition and Epidemiology
  73. [73]

    Mortimer JE, Barsevick AM, Bennett CL et al.. “Studying cancer-related fatigue: report of the NCCN scientific research committee.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 21147900 ↗

    L5OTHERCited in: Definition and Epidemiology
  74. [74]

    Heist RS, Sands J, Bardia A et al.. “Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.” Cancer treatment reviews (2024). PMID: 38502995 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers
  75. [75]

    Trapani D, Ginsburg O, Fadelu T et al.. “Global challenges and policy solutions in breast cancer control.” Cancer treatment reviews (2022). PMID: 35074727 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Management Overview
  76. [76]

    Cucciniello L, Garufi G, Di Rienzo R et al.. “Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome.” Cancer treatment reviews (2023). PMID: 37751658 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
  77. [77]

    Gómez-Raposo C, Zambrana Tévar F, Sereno Moyano M et al.. “Male breast cancer.” Cancer treatment reviews (2010). PMID: 20193984 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  78. [78]

    Rached L, Laparra A, Sakkal M et al.. “Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations.” Cancer treatment reviews (2024). PMID: 38729086 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  79. [79]

    Bozovic-Spasojevic I, Azambuja E, McCaskill-Stevens W et al.. “Chemoprevention for breast cancer.” Cancer treatment reviews (2012). PMID: 21856081 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation
  80. [80]

    Corti C, Antonarelli G, Criscitiello C et al.. “Targeting brain metastases in breast cancer.” Cancer treatment reviews (2021). PMID: 34953200 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  81. [81]

    Tryfonidis K, Zardavas D, Cardoso F. “Small breast cancers: when and how to treat.” Cancer treatment reviews (2014). PMID: 25315501 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors
  82. [82]

    Bartsch R, Jerzak KJ, Larrouquere L et al.. “Pharmacotherapy for leptomeningeal disease in breast cancer.” Cancer treatment reviews (2023). PMID: 38118373 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Prognosis and Prognostic Factors
  83. [83]

    Mederos N, Friedlaender A, Peters S et al.. “Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer.” ESMO open (2020). PMID: 33148544 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, History and Evolution of Treatment
  84. [84]

    Zagouri F, Dimitrakakis C, Marinopoulos S et al.. “Cancer in pregnancy: disentangling treatment modalities.” ESMO open (2016). PMID: 27843602 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation
  85. [85]

    Pondé NF, Lambertini M, de Azambuja E. “Twenty years of anti-HER2 therapy-associated cardiotoxicity.” ESMO open (2016). PMID: 27843627 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  86. [86]

    Stavrou E, Winer EP, Lin NU. “How we treat HER2-positive brain metastases.” ESMO open (2021). PMID: 34482180 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  87. [87]

    Kerr J, Anderson C, Lippman SM. “Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.” The Lancet. Oncology (2017). PMID: 28759385 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  88. [88]

    Bray F, Parkin DM. “Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.” The Lancet. Oncology (2022). PMID: 35550275 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  89. [89]

    Lee M, Goldenberg SM, Dávila-Conn V et al.. “Social Determinants of Health and Cardiovascular Disease-Related Outcome Disparities Among Breast Cancer Survivors: A Systematic Review.” Journal of the American Heart Association (2026). PMID: 42396821 ↗

    L5SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview
  90. [90]

    Tarantino P, Modi S, Tolaney SM et al.. “Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.” JAMA oncology (2021). PMID: 34647966 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview
  91. [91]

    Hanker AB, Sudhan DR, Arteaga CL. “Overcoming Endocrine Resistance in Breast Cancer.” Cancer cell (2020). PMID: 32289273 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
  92. [92]

    Kodack DP, Askoxylakis V, Ferraro GB et al.. “Emerging strategies for treating brain metastases from breast cancer.” Cancer cell (2015). PMID: 25670078 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Histopathology and Molecular Biology
  93. [93]

    Deng C, Wen X, Liu S et al.. “Effects of opioid-free anesthesia on postoperative anxiety in patients undergoing modified radical mastectomy for breast cancer: a randomized controlled trial.” BMC anesthesiology (2026). PMID: 42399751 ↗

    L1RCTCited in: Definition and Epidemiology
  94. [94]

    Das P, Dutta S, Maji S et al.. “Safety and efficacy of Efbemalenograstim alfa for patients at risk for chemotherapy-induced neutropenia: A Systematic review and Meta-analysis.” Pharmacology (2026). PMID: 42400926 ↗

    L1SR_OBSCited in: Definition and Epidemiology
  95. [95]

    Kennecke H, Yerushalmi R, Woods R et al.. “Metastatic behavior of breast cancer subtypes.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20498394 ↗

    L2OTHERCited in: Definition and Epidemiology, Special Populations
  96. [96]

    Jain S, Vahdat LT. “Eribulin mesylate.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 21859830 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  97. [97]

    Metzger-Filho O, Winer EP, Krop I. “Pertuzumab: optimizing HER2 blockade.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 23942091 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  98. [98]

    Lin NU, Winer EP. “Brain metastases: the HER2 paradigm.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17363517 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Management Overview
  99. [99]

    Hirbe A, Morgan EA, Uluçkan O et al.. “Skeletal complications of breast cancer therapies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17062720 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  100. [100]

    Reeder-Hayes KE, Anderson BO. “Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28572260 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  101. [101]

    Friedenreich CM, Neilson HK, Farris MS et al.. “Physical Activity and Cancer Outcomes: A Precision Medicine Approach.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27407093 ↗

    L2REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation
  102. [102]

    Olopade OI, Grushko TA, Nanda R et al.. “Advances in breast cancer: pathways to personalized medicine.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 19088015 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation
  103. [103]

    Bardia A, Hurvitz S. “Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29884743 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Staging
  104. [104]

    Biggar RJ. “Molecular pathways: digoxin use and estrogen-sensitive cancers--risks and possible therapeutic implications.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22368159 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
  105. [105]

    Aragon-Ching JB, Zujewski JA. “CNS metastasis: an old problem in a new guise.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17363516 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  106. [106]

    Facondo G, Prisco A, Reverberi C et al.. “Incidence and Predictors of Fat Necrosis After Single-Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer: Results From a Phase II Clinical Trial.” International journal of radiation oncology, biology, physics (2026). PMID: 42425251 ↗

    L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Clinical Presentation
  107. [107]

    Hassoub G, El-Bassiouny NA, Abdelkader Y et al.. “Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial.” BMC pharmacology & toxicology (2026). PMID: 42401951 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment, Special Populations
  108. [108]

    Chowdhury AM, Halaseh SA, Joseph D et al.. “Breast cancer clinical trials in low- and middle-income countries (LMICs).” Ecancermedicalscience (2026). PMID: 42416228 ↗

    L2TRIAL_NONRANDOMCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  109. [109]

    Powell CA, Modi S, Iwata H et al.. “Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.” ESMO open (2022). PMID: 35963179 ↗

    L4OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations
  110. [110]

    Huang Z, Wang J, Liu H et al.. “Global trends in adolescent and young adult female cancer burden, 1990-2021: insights from the Global Burden of Disease study.” ESMO open (2024). PMID: 39426082 ↗

    L2OTHERCited in: Definition and Epidemiology
  111. [111]

    Kong W, He Z, Li D et al.. “Impact of depression on treatment response and survival among patients with breast cancer: A multi-institutional retrospective cohort study.” Breast (Edinburgh, Scotland) (2026). PMID: 42419252 ↗

    L3COHORTCited in: Definition and Epidemiology
  112. [112]

    Gentilini OD, Botteri E, Sangalli C et al.. “Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.” JAMA oncology (2023). PMID: 37733364 ↗

    L1OTHERCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis, Imaging, Management Overview
  113. [113]

    Giannakeas V, Lim DW, Narod SA. “Bilateral Mastectomy and Breast Cancer Mortality.” JAMA oncology (2024). PMID: 39052262 ↗

    L2OTHERCited in: Definition and Epidemiology, Management Overview, Special Populations
  114. [114]

    McVicker L, Labeit AM, Coupland CAC et al.. “Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer.” JAMA oncology (2024). PMID: 37917089 ↗

    L3OTHERCited in: Definition and Epidemiology, Clinical Presentation, Management Overview, Special Populations
  115. [115]

    Chen S, Cao Z, Prettner K et al.. “Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050.” JAMA oncology (2023). PMID: 36821107 ↗

    L5OTHERCited in: Definition and Epidemiology, Management Overview
  116. [116]

    Montagna G, Mrdutt MM, Sun SX et al.. “Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.” JAMA oncology (2024). PMID: 38662396 ↗

    L3OTHERCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis, Imaging, Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
  117. [117]

    Fitzmaurice C, Abate D, Abbasi N et al.. “Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.” JAMA oncology (2019). PMID: 31560378 ↗

    L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  118. [118]

    Yofe I, Shami T, Cohen N et al.. “Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary.” Cancer discovery (2023). PMID: 37756565 ↗

    L5OTHERCited in: Definition and Epidemiology
  119. [119]

    Saura C, Ortiz C, Matito J et al.. “Early-Stage Breast Cancer Detection in Breast Milk.” Cancer discovery (2023). PMID: 37704212 ↗

    L4OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Molecular Diagnostics and Biomarkers
  120. [120]

    Shiels MS, Lipkowitz S, Campos NG et al.. “Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047.” Cancer discovery (2023). PMID: 37067240 ↗

    L5OTHERCited in: Definition and Epidemiology
  121. [121]

    Pradat Y, Viot J, Yurchenko AA et al.. “Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer.” Cancer discovery (2023). PMID: 36862804 ↗

    L4OTHERCited in: Definition and Epidemiology, Histopathology and Molecular Biology
  122. [122]

    Sreekumar A, Blankemeyer E, Sterner CJ et al.. “Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy.” Cancer discovery (2026). PMID: 41370830 ↗

    L5OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
  123. [123]

    . “By the Numbers: Cancer Mortality, 2011-2015.” Cancer discovery (2018). PMID: 30076139 ↗

    L5OTHERCited in: Definition and Epidemiology
  124. [124]

    Cann CG, Eng C. “Cancer in the Prime of Life: Etiologic Insights and Supportive Oncologic Interventions for the Rising Burden of Young Adult Cancer.” Cancer discovery (2025). PMID: 40605507 ↗

    L5OTHERCited in: Definition and Epidemiology
  125. [125]

    Liu H, Paddock MN, Wang H et al.. “The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.” Cancer discovery (2020). PMID: 32513774 ↗

    L5OTHERCited in: Definition and Epidemiology
  126. [126]

    Feng Y, Pan TC, Pant DK et al.. “SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling.” Cancer discovery (2014). PMID: 24786206 ↗

    L5OTHERCited in: Definition and Epidemiology
  127. [127]

    Pinato DJ, Zambelli A, Aguilar-Company J et al.. “Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.” Cancer discovery (2020). PMID: 32737082 ↗

    L2OTHERCited in: Definition and Epidemiology
  128. [128]

    Martini R, Delpe P, Chu TR et al.. “African Ancestry-Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent.” Cancer discovery (2022). PMID: 36121736 ↗

    L3OTHERCited in: Definition and Epidemiology, Histopathology and Molecular Biology
  129. [129]

    Sceneay J, Goreczny GJ, Wilson K et al.. “Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.” Cancer discovery (2019). PMID: 31217296 ↗

    L5OTHERCited in: Definition and Epidemiology, Clinical Presentation
  130. [130]

    Xiao Y, Cong M, Li J et al.. “Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation.” Cancer cell (2021). PMID: 33450198 ↗

    L5OTHERCited in: Definition and Epidemiology
  131. [131]

    Rozalén C, Sangrador I, Avalle S et al.. “TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak.” Cancer cell (2025). PMID: 40645187 ↗

    L5OTHERCited in: Definition and Epidemiology
  132. [132]

    Sreekumar A, Lu M, Choudhury B et al.. “B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling.” Cancer cell (2023). PMID: 38065100 ↗

    L5OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition
  133. [133]

    Chang G, Shi L, Ye Y et al.. “YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis.” Cancer cell (2020). PMID: 33125861 ↗

    L4OTHERCited in: Definition and Epidemiology
  134. [134]

    Ooms LM, Binge LC, Davies EM et al.. “The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis.” Cancer cell (2015). PMID: 26267533 ↗

    L5OTHERCited in: Definition and Epidemiology
  135. [135]

    Grolleman JE, de Voer RM, Elsayed FA et al.. “Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype.” Cancer cell (2019). PMID: 30753826 ↗

    L4OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition, Histopathology and Molecular Biology
  136. [136]

    Sgroi DC. “Breast cancer SRC activity: bad to the bone.” Cancer cell (2009). PMID: 19573804 ↗

    L5OTHERCited in: Definition and Epidemiology
  137. [137]

    Khan M, Dekate K, Dhorajiwala S et al.. “Establishing The Role of Transforming Growth Factor Beta Regulator 4 In Cancer Progression: A Systematic Review.” Journal of stomatology, oral and maxillofacial surgery (2026). PMID: 42419424 ↗

    L2SR_OBSCited in: Definition and Epidemiology
  138. [138]

    Liu Z, Wang X, Gai J et al.. “Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study.” Frontiers in oncology (2026). PMID: 42434737 ↗

    L2COHORTCited in: Definition and Epidemiology
  139. [139]

    Hussein AM. “The state of cancer in Somalia: a comprehensive six-year retrospective study.” BMC cancer (2026). PMID: 42432552 ↗

    L4COHORTCited in: Definition and Epidemiology
  140. [140]

    de Almeida CC, Santos DH, Machado Magalhães PL et al.. “Ten-year temporal distribution of brain metastases after breast cancer: a global cohort study.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2026). PMID: 42419089 ↗

    L2COHORTCited in: Definition and Epidemiology, Clinical Presentation
  141. [141]

    Wen Q, Zhang Y, Qiao L et al.. “Burden of cardiovascular diseases in breast cancer survivors: a 9-year retrospective cohort study based on regional medical data in Inner Mongolia China.” Cardio-oncology (London, England) (2026). PMID: 42415223 ↗

    L2COHORTCited in: Definition and Epidemiology, Clinical Presentation
  142. [142]

    Abelman RO, Wu B, Barnes H et al.. “TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39745368 ↗

    L2OTHERCited in: Definition and Epidemiology
  143. [143]

    Daly MB, Pal T, Berry MP et al.. “Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33406487 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Management Overview, History and Evolution of Treatment
  144. [144]

    Bevers TB, Ward JH, Arun BK et al.. “Breast Cancer Risk Reduction, Version 2.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26150582 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, History and Evolution of Treatment
  145. [145]

    Bevers TB, Helvie M, Bonaccio E et al.. “Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30442736 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Clinical Presentation, Biopsy and Histologic Diagnosis
  146. [146]

    Vogelbaum MA, Brown PD, Messersmith H et al.. “Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34932393 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, History and Evolution of Treatment
  147. [147]

    Runowicz CD, Leach CR, Henry NL et al.. “American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26644543 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Clinical Presentation, History and Evolution of Treatment
  148. [148]

    Park KH, Loibl S, Sohn J et al.. “Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.” ESMO open (2024). PMID: 38796284 ↗

    L1GUIDELINECited in: Risk Factors and Prevention, Staging
  149. [149]

    Ruddy KJ, Winer EP. “Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23425944 ↗

    L2SR_OBSCited in: Risk Factors and Prevention
  150. [150]

    Islami F, Liu Y, Jemal A et al.. “Breastfeeding and breast cancer risk by receptor status--a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26504151 ↗

    L2SR_OBSCited in: Risk Factors and Prevention
  151. [151]

    Di Leo A, Jerusalem G, Petruzelka L et al.. “Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20855825 ↗

    L1RCTCited in: Risk Factors and Prevention
  152. [152]

    Wu AH, Wu J, Tseng C et al.. “Air Pollution and Breast Cancer Incidence in the Multiethnic Cohort Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39378392 ↗

    L2COHORTCited in: Risk Factors and Prevention
  153. [153]

    Mayer EL, Fesl C, Hlauschek D et al.. “Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 34995105 ↗

    L1RCTCited in: Risk Factors and Prevention
  154. [154]

    Chen T, Xu T, Li Y et al.. “Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.” Cancer treatment reviews (2010). PMID: 20952131 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  155. [155]

    Lambertini M, Santoro L, Del Mastro L et al.. “Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.” Cancer treatment reviews (2016). PMID: 27529149 ↗

    L2SR_OBSCited in: Risk Factors and Prevention, Special Populations
  156. [156]

    Wen H, Deng G, Shi X et al.. “Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies.” ESMO open (2024). PMID: 38442453 ↗

    L2SR_OBSCited in: Risk Factors and Prevention
  157. [157]

    Di Lauro V, Barchiesi G, Martorana F et al.. “Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.” ESMO open (2022). PMID: 36399953 ↗

    L2SR_OBSCited in: Risk Factors and Prevention
  158. [158]

    Yazgan SC, Yekedüz E, Akkuş E et al.. “Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis.” ESMO open (2025). PMID: 41027069 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  159. [159]

    . “Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.” The Lancet. Oncology (2012). PMID: 23084519 ↗

    L2SR_OBSCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Special Populations
  160. [160]

    Kim GM, Kim MH, Park HS et al.. “A prospective study for brain metastasis imaging screening in patients with advanced HER2-positive or triple-negative breast cancer.” ESMO open (2026). PMID: 41818850 ↗

    L4COHORTCited in: Risk Factors and Prevention, Imaging
  161. [161]

    Lång K, Josefsson V, Larsson AM et al.. “Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study.” The Lancet. Oncology (2023). PMID: 37541274 ↗

    L1RCTCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  162. [162]

    Krag DN, Anderson SJ, Julian TB et al.. “Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.” The Lancet. Oncology (2010). PMID: 20863759 ↗

    L1RCTCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  163. [163]

    Kunkler IH, Williams LJ, Jack WJ et al.. “Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.” The Lancet. Oncology (2015). PMID: 25637340 ↗

    L1RCTCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Staging, Special Populations
  164. [164]

    Meattini I, De Santis MC, Visani L et al.. “Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial.” The Lancet. Oncology (2024). PMID: 39675376 ↗

    L1RCTCited in: Risk Factors and Prevention, Staging
  165. [165]

    Decensi A, Dunn BK, Puntoni M et al.. “Exemestane for breast cancer prevention: a critical shift?” Cancer discovery (2012). PMID: 22585166 ↗

    L5RCTCited in: Risk Factors and Prevention, History and Evolution of Treatment, Special Populations
  166. [166]

    Charton E, Baldini C, Fayet Y et al.. “Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.” ESMO open (2023). PMID: 37536254 ↗

    L2TRIAL_NONRANDOMCited in: Risk Factors and Prevention
  167. [167]

    Stolarova L, Kleiblova P, Zemankova P et al.. “ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37449874 ↗

    L3SR_OBSCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  168. [168]

    Juneja V, Keegan P, Gootenberg JE et al.. “Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18519748 ↗

    L5SR_OBSCited in: Risk Factors and Prevention
  169. [169]

    Daly MB, Pal T, Maxwell KN et al.. “NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37856201 ↗

    L1OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  170. [170]

    Bevers TB, Niell BL, Baker JL et al.. “NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37673117 ↗

    L1OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  171. [171]

    Ng AK, Travis LB. “Radiation therapy and breast cancer risk.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19930978 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  172. [172]

    Palesh O, Aldridge-Gerry A, Ulusakarya A et al.. “Sleep disruption in breast cancer patients and survivors.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 24335687 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation
  173. [173]

    Pinsky RW, Helvie MA. “Mammographic breast density: effect on imaging and breast cancer risk.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20971840 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Imaging
  174. [174]

    Mao X, He W, Humphreys K et al.. “Factors Associated With False-Positive Recalls in Mammography Screening.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 36791753 ↗

    L2OTHERCited in: Risk Factors and Prevention
  175. [175]

    Lehman CD, Smith RA. “The role of MRI in breast cancer screening.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19930977 ↗

    L1REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Imaging
  176. [176]

    Lee JM, Ichikawa L, Su YR et al.. “Comparative Accuracy of Digital Breast Tomosynthesis and Digital Mammography for Surveillance After Breast Cancer Treatment.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41101341 ↗

    L2OTHERCited in: Risk Factors and Prevention
  177. [177]

    Halvorsrud K, Fowler H, Hamad W et al.. “Improving Breast Cancer Outcomes by Enhanced Activities in Early Detection and Diagnosis: An Umbrella Review and Meta-Analyses of Randomised Controlled Trials in High-Income Contexts With Universal Healthcare Coverage.” Cancer control : journal of the Moffitt Cancer Center (2026). PMID: 42400473 ↗

    L1SR_MA_RCTCited in: Risk Factors and Prevention, Clinical Presentation
  178. [178]

    Kim J, Munster PN. “Estrogens and breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39522613 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  179. [179]

    Olmos D, Lorente D, Alameda D et al.. “Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38417742 ↗

    L2OTHERCited in: Risk Factors and Prevention
  180. [180]

    Van Baelen K, Sawyer E, Van Cauwenberge J et al.. “Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40701440 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors
  181. [181]

    Niravath P. “Aromatase inhibitor-induced arthralgia: a review.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23471104 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation
  182. [182]

    Gluz O, Liedtke C, Gottschalk N et al.. “Triple-negative breast cancer--current status and future directions.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19901010 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  183. [183]

    Akamandisa MP, Boddicker NJ, Yadav S et al.. “Association of gene variant type and location with breast cancer risk in the general population.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40288678 ↗

    L3OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  184. [184]

    Shiovitz S, Korde LA. “Genetics of breast cancer: a topic in evolution.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25605744 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  185. [185]

    Curigliano G, Spitaleri G, Pietri E et al.. “Breast cancer vaccines: a clinical reality or fairy tale?” Annals of oncology : official journal of the European Society for Medical Oncology (2005). PMID: 16293674 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  186. [186]

    Hosseini SS, Oreizy HR, Savabi-Esfahani M. “Psychological consequences of mammography screening recommendations: a prospective cohort study in Iran.” BMC psychology (2026). PMID: 42432808 ↗

    L2COHORTCited in: Risk Factors and Prevention, History and Evolution of Treatment
  187. [187]

    Lucarelli AP, Martins MM, Teruya MM et al.. “Systematic Review and Meta-Analysis: Association Between Circulating and Tissue Levels of Selenium and Zinc and Breast Cancer Risk.” The breast journal (2026). PMID: 42390038 ↗

    L1SR_OBSCited in: Risk Factors and Prevention
  188. [188]

    Tung N, Lin NU, Kidd J et al.. “Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26976419 ↗

    L4OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Staging, Special Populations
  189. [189]

    Yala A, Mikhael PG, Strand F et al.. “Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34767469 ↗

    L2OTHERCited in: Risk Factors and Prevention
  190. [190]

    Wentzensen N, Poole EM, Trabert B et al.. “Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27325851 ↗

    L2OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology
  191. [191]

    Paik S, Tang G, Shak S et al.. “Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16720680 ↗

    L1OTHERCited in: Risk Factors and Prevention
  192. [192]

    Allen I, Hassan H, Walburga Y et al.. “Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39475295 ↗

    L2OTHERCited in: Risk Factors and Prevention
  193. [193]

    Phillips KA, Kotsopoulos J, Domchek SM et al.. “Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39356978 ↗

    L2OTHERCited in: Risk Factors and Prevention
  194. [194]

    Tian R, Wiley B, Liu J et al.. “Clonal Hematopoiesis and Risk of Incident Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36480766 ↗

    L3OTHERCited in: Risk Factors and Prevention
  195. [195]

    Mars N, Kerminen S, Tamlander M et al.. “Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38422475 ↗

    L2OTHERCited in: Risk Factors and Prevention
  196. [196]

    Jiralerspong S, Goodwin PJ. “Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27903149 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  197. [197]

    Robsahm TE, Støer NC, Bø K et al.. “Exercise trajectories and current exercise and risk of breast cancer: a cohort study of 325,953 women who participated in BreastScreen Norway.” Cancer causes & control : CCC (2026). PMID: 42400682 ↗

    L2COHORTCited in: Risk Factors and Prevention
  198. [198]

    Gheysen M, Punie K, Wildiers H et al.. “Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review.” Cancer treatment reviews (2024). PMID: 39293125 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview
  199. [199]

    Qiu P, Yu X, Zheng F et al.. “Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications.” Cancer treatment reviews (2025). PMID: 40540857 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  200. [200]

    Calabrese A, von Arx C, Tafuti AA et al.. “Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes.” Cancer treatment reviews (2024). PMID: 38870570 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  201. [201]

    McCartney A, Vignoli A, Biganzoli L et al.. “Metabolomics in breast cancer: A decade in review.” Cancer treatment reviews (2018). PMID: 29775779 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Prognosis and Prognostic Factors
  202. [202]

    Nielsen I, Gordon S, Selby A. “Breast cancer-related lymphoedema risk reduction advice: a challenge for health professionals.” Cancer treatment reviews (2008). PMID: 18691823 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  203. [203]

    Musolino A, Boggiani D, Sikokis A et al.. “Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers.” Cancer treatment reviews (2015). PMID: 26827687 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  204. [204]

    Venetis K, Invernizzi M, Sajjadi E et al.. “Cellular immunotherapy in breast cancer: The quest for consistent biomarkers.” Cancer treatment reviews (2020). PMID: 32889360 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  205. [205]

    Albanell J, Ciruelos EM, Lluch A et al.. “Trastuzumab in small tumours and in elderly women.” Cancer treatment reviews (2013). PMID: 23659993 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  206. [206]

    Müller V, Bachelot T, Curigliano G et al.. “Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer.” Cancer treatment reviews (2024). PMID: 39612906 ↗

    L1REVIEW_NARRATIVECited in: Risk Factors and Prevention
  207. [207]

    Del Re M, Michelucci A, Simi P et al.. “Pharmacogenetics of anti-estrogen treatment of breast cancer.” Cancer treatment reviews (2011). PMID: 21917382 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  208. [208]

    Shami R, Salgado R, Bardia A et al.. “Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06.” ESMO open (2025). PMID: 40494041 ↗

    L4OTHERCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
  209. [209]

    Tobias J, Garner-Spitzer E, Drinić M et al.. “Vaccination against Her-2/neu, with focus on peptide-based vaccines.” ESMO open (2022). PMID: 35026721 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  210. [210]

    Gutzeit A, Dubsky P, Matoori S et al.. “Breast cancer in Switzerland: a comparison between organized-screening versus opportunistic-screening cantons.” ESMO open (2024). PMID: 39321720 ↗

    L2OTHERCited in: Risk Factors and Prevention, Staging
  211. [211]

    Adams E, Wildiers H, Neven P et al.. “Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.” ESMO open (2021). PMID: 34225076 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
  212. [212]

    Finn E, Sardo Infirri S, Clarke CS et al.. “Li Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriers.” ESMO open (2025). PMID: 40840234 ↗

    L4OTHERCited in: Risk Factors and Prevention, Staging
  213. [213]

    Chambers P, Forster MD, Patel A et al.. “Development and validation of a risk score (Delay-7) to predict the occurrence of a treatment delay following cycle 1 chemotherapy.” ESMO open (2022). PMID: 36542904 ↗

    L2OTHERCited in: Risk Factors and Prevention
  214. [214]

    Innella G, Erini G, De Leo A et al.. “Development of a risk score based on clinical-pathological features to predict the presence of germline BRCA1/2 pathogenic variants in ovarian cancer patients.” ESMO open (2025). PMID: 40580611 ↗

    L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  215. [215]

    Maurer C, Tulpin L, Moreau M et al.. “Risk factors for the development of brain metastases in patients with HER2-positive breast cancer.” ESMO open (2018). PMID: 30425844 ↗

    L2OTHERCited in: Risk Factors and Prevention
  216. [216]

    Fan L, Strasser-Weippl K, Li JJ et al.. “Breast cancer in China.” The Lancet. Oncology (2014). PMID: 24872111 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Management Overview
  217. [217]

    Franzoi MA, Agostinetto E, Perachino M et al.. “Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.” The Lancet. Oncology (2021). PMID: 33891888 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Management Overview, Prognosis and Prognostic Factors
  218. [218]

    Denkert C, von Minckwitz G, Darb-Esfahani S et al.. “Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.” The Lancet. Oncology (2017). PMID: 29233559 ↗

    L1OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  219. [219]

    Darby SC, Ewertz M, McGale P et al.. “Risk of ischemic heart disease in women after radiotherapy for breast cancer.” The New England journal of medicine (2013). PMID: 23484825 ↗

    L3OTHERCited in: Risk Factors and Prevention
  220. [220]

    Hu C, Hart SN, Gnanaolivu R et al.. “A Population-Based Study of Genes Previously Implicated in Breast Cancer.” The New England journal of medicine (2021). PMID: 33471974 ↗

    L3OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  221. [221]

    Welch HG, Prorok PC, O'Malley AJ et al.. “Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.” The New England journal of medicine (2016). PMID: 27732805 ↗

    L2OTHERCited in: Risk Factors and Prevention, Staging
  222. [222]

    Chun K, Tran-Dang MP, Cornett P et al.. “Outreach to Native Hawaiian and Pacific Islander communities to increase breast cancer screening and clinical trial awareness.” BMC cancer (2026). PMID: 42420902 ↗

    L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention
  223. [223]

    Cheng HH, Shevach JW, Castro E et al.. “BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.” JAMA oncology (2024). PMID: 39052257 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Management Overview
  224. [224]

    Goddard KAB, Feuer EJ, Mandelblatt JS et al.. “Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.” JAMA oncology (2025). PMID: 39636625 ↗

    L2OTHERCited in: Risk Factors and Prevention, Special Populations
  225. [225]

    Hadizadeh F, Koteci A, Karlsson T et al.. “Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women.” JAMA oncology (2025). PMID: 41165687 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  226. [226]

    Hansford S, Kaurah P, Li-Chang H et al.. “Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.” JAMA oncology (2015). PMID: 26182300 ↗

    L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Special Populations
  227. [227]

    Lubinski J, Kotsopoulos J, Moller P et al.. “MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations.” JAMA oncology (2024). PMID: 38421676 ↗

    L2OTHERCited in: Risk Factors and Prevention, Imaging, Special Populations
  228. [228]

    Bolze A, Cirulli ET, Hajek C et al.. “The Potential of Genetics in Identifying Women at Lower Risk of Breast Cancer.” JAMA oncology (2024). PMID: 38153744 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  229. [229]

    O'Brien KM, Keil AP, Taylor JA et al.. “Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women.” JAMA oncology (2025). PMID: 41066089 ↗

    L3OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  230. [230]

    Fitzmaurice C, Allen C, Barber RM et al.. “Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.” JAMA oncology (2017). PMID: 27918777 ↗

    L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation
  231. [231]

    Wei X, Mansour L, Oxley S et al.. “Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention.” JAMA oncology (2025). PMID: 40705362 ↗

    L5OTHERCited in: Risk Factors and Prevention
  232. [232]

    Zhang Y, Rodriguez J, Mao X et al.. “Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer.” JAMA oncology (2025). PMID: 40146116 ↗

    L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  233. [233]

    Brantley KD, Rosenberg SM, Collins LC et al.. “Second Primary Breast Cancer in Young Breast Cancer Survivors.” JAMA oncology (2024). PMID: 38602683 ↗

    L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  234. [234]

    Barac A, Chou J, Shara N et al.. “Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer Treatment.” JAMA oncology (2025). PMID: 41129144 ↗

    L2OTHERCited in: Risk Factors and Prevention
  235. [235]

    Li T, Su YR, Lee JM et al.. “Tomosynthesis vs Digital Mammography Screening in Women with a Family History of Breast Cancer.” JAMA oncology (2025). PMID: 40402477 ↗

    L2OTHERCited in: Risk Factors and Prevention
  236. [236]

    Aftimos P, Oliveira M, Irrthum A et al.. “Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.” Cancer discovery (2021). PMID: 34183353 ↗

    L4OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
  237. [237]

    Neill NJ, Satpathy S, Krug K et al.. “Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer.” Cancer discovery (2025). PMID: 40778818 ↗

    L5OTHERCited in: Risk Factors and Prevention
  238. [238]

    Langille E, Al-Zahrani KN, Ma Z et al.. “Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer.” Cancer discovery (2022). PMID: 36108220 ↗

    L5OTHERCited in: Risk Factors and Prevention
  239. [239]

    Brough R, Frankum JR, Sims D et al.. “Functional viability profiles of breast cancer.” Cancer discovery (2011). PMID: 21984977 ↗

    L5OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
  240. [240]

    Vijai J, Topka S, Villano D et al.. “A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.” Cancer discovery (2016). PMID: 27655433 ↗

    L3OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Special Populations
  241. [241]

    . “Q&A: Olufunmilayo Olopade on Genomics and Breast Cancer.” Cancer discovery (2020). PMID: 32051175 ↗

    L5OTHERCited in: Risk Factors and Prevention
  242. [242]

    . “Hormone levels predict long-term breast cancer risk.” Cancer discovery (2012). PMID: 23230205 ↗

    L5OTHERCited in: Risk Factors and Prevention
  243. [243]

    Liao C, Zhang Y, Fan C et al.. “Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer.” Cancer discovery (2020). PMID: 32690540 ↗

    L5OTHERCited in: Risk Factors and Prevention
  244. [244]

    Littlepage LE, Adler AS, Kouros-Mehr H et al.. “The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.” Cancer discovery (2012). PMID: 22728437 ↗

    L5OTHERCited in: Risk Factors and Prevention
  245. [245]

    . “3D imaging finds more breast cancers.” Cancer discovery (2014). PMID: 25185169 ↗

    L5OTHERCited in: Risk Factors and Prevention, Imaging
  246. [246]

    Chin YR, Yuan X, Balk SP et al.. “PTEN-deficient tumors depend on AKT2 for maintenance and survival.” Cancer discovery (2014). PMID: 24838891 ↗

    L5OTHERCited in: Risk Factors and Prevention
  247. [247]

    Yang Z, Liu X, Zhu J et al.. “Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1.” Cancer cell (2024). PMID: 39672166 ↗

    L5OTHERCited in: Risk Factors and Prevention, Management Overview
  248. [248]

    Goddard ET, Linde MH, Srivastava S et al.. “Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.” Cancer cell (2024). PMID: 38194912 ↗

    L5OTHERCited in: Risk Factors and Prevention
  249. [249]

    Polyak K. “Pregnancy and breast cancer: the other side of the coin.” Cancer cell (2006). PMID: 16530699 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Special Populations
  250. [250]

    Hutten SJ, de Bruijn R, Lutz C et al.. “A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.” Cancer cell (2023). PMID: 37116492 ↗

    L5OTHERCited in: Risk Factors and Prevention, History and Evolution of Treatment
  251. [251]

    Visvader JE. “Midkine links aging with breast cancer-A new predictor of cancer risk.” Cancer cell (2024). PMID: 39366374 ↗

    L5OTHERCited in: Risk Factors and Prevention
  252. [252]

    Geuijen CAW, De Nardis C, Maussang D et al.. “Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.” Cancer cell (2018). PMID: 29763625 ↗

    L5OTHERCited in: Risk Factors and Prevention
  253. [253]

    Lu J, Guo H, Treekitkarnmongkol W et al.. “14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition.” Cancer cell (2009). PMID: 19732720 ↗

    L5OTHERCited in: Risk Factors and Prevention
  254. [254]

    Fennell NB, Abukar S, Kuhn I et al.. “Experiences of implementation of personalised risk estimates for breast cancer in clinical practice: a systematic review and qualitative synthesis.” Journal of community genetics (2026). PMID: 42405977 ↗

    L2SR_OBSCited in: Risk Factors and Prevention, History and Evolution of Treatment
  255. [255]

    Medford AJ, Moy B, Spring LM et al.. “Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37477704 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview
  256. [256]

    Schneider BP, Winer EP, Foulkes WD et al.. “Triple-negative breast cancer: risk factors to potential targets.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 19088017 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Histopathology and Molecular Biology
  257. [257]

    Griguolo G, Bottosso M, Landa G et al.. “Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41661219 ↗

    L4OTHERCited in: Risk Factors and Prevention
  258. [258]

    Jilderda MF, Zhang Y, Rebattu V et al.. “Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40145943 ↗

    L2OTHERCited in: Risk Factors and Prevention
  259. [259]

    Barber L, Gerke T, Markt SC et al.. “Family History of Breast or Prostate Cancer and Prostate Cancer Risk.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30082473 ↗

    L2OTHERCited in: Risk Factors and Prevention
  260. [260]

    Howard FM, Fasching PA, Santa-Maria CA et al.. “Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41213110 ↗

    L3OTHERCited in: Risk Factors and Prevention
  261. [261]

    Thursby SJ, Jin Z, Blum J et al.. “Epigenetic Instability-Based Metrics in Cell-Free DNA for Early Cancer Detection.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41591979 ↗

    L3OTHERCited in: Risk Factors and Prevention
  262. [262]

    Turner NC, Reis-Filho JS. “Tackling the diversity of triple-negative breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24298068 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Histopathology and Molecular Biology
  263. [263]

    Miller SM, Roussi P, Daly MB et al.. “New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20829330 ↗

    L2REVIEW_NARRATIVECited in: Risk Factors and Prevention
  264. [264]

    Brand JS, Hedayati E, Humphreys K et al.. “Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27803117 ↗

    L2OTHERCited in: Risk Factors and Prevention
  265. [265]

    Sangi Nasab Lahijan A, Abdollahi S, Miri SR et al.. “Circulating Plasma Circular RNAs hsa_circ_0001785 and hsa_circ_0079876 as Promising Noninvasive Diagnostic Biomarkers for Breast Cancer: A Case-Control Study.” The breast journal (2026). PMID: 42402856 ↗

    L3CASE_CONTROLCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
  266. [266]

    Houssa N, Abdelalim S, Elmouki I. “Algebraic evaluation of optimization in tumors classification with numerical assessments via a flask-react web interface.” Frontiers in digital health (2026). PMID: 42434374 ↗

    L5OTHERCited in: Risk Factors and Prevention
  267. [267]

    Sheppard AJ, Sutradhar R, Liu N et al.. “Population-Level Outcomes for Screening Program Cancers in First Nations People in Ontario, Canada.” JAMA network open (2026). PMID: 42430169 ↗

    L3OTHERCited in: Risk Factors and Prevention
  268. [268]

    Comeaux JG, Gutierrez N, Ricker CN et al.. “Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or with empirically increased breast cancer risk.” Breast cancer research and treatment (2026). PMID: 42430009 ↗

    L4OTHERCited in: Risk Factors and Prevention, Imaging
  269. [269]

    Mühlhausen L, Kocher M, Karadachi HH et al.. “Leptomeningeal disease (LMD) after resection of brain metastases: results of the multicenter SUBAROMA study.” Journal of neuro-oncology (2026). PMID: 42429857 ↗

    L3OTHERCited in: Risk Factors and Prevention, Imaging, Management Overview
  270. [270]

    Lundorff CMB, Njor SH, Madsen SL et al.. “Socioeconomic variation in adherence to follow-up after an abnormal screening mammogram in the Danish breast cancer screening program.” Breast cancer research and treatment (2026). PMID: 42423753 ↗

    L3OTHERCited in: Risk Factors and Prevention
  271. [271]

    Telli ML, Gradishar WJ, Ward JH. “NCCN Guidelines Updates: Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31117035 ↗

    L1GUIDELINECited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment
  272. [272]

    Carlson RW, Moench SJ, Hammond ME et al.. “HER2 testing in breast cancer: NCCN Task Force report and recommendations.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16813731 ↗

    L5GUIDELINECited in: Genetics and Hereditary Predisposition, Clinical Presentation, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  273. [273]

    Hassett MJ, Somerfield MR, Baker ER et al.. “Management of Male Breast Cancer: ASCO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32058842 ↗

    L1GUIDELINECited in: Genetics and Hereditary Predisposition, Imaging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  274. [274]

    Bedrosian I, Somerfield MR, Achatz MI et al.. “Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38175972 ↗

    L1GUIDELINECited in: Genetics and Hereditary Predisposition
  275. [275]

    Henry NL, Somerfield MR, Dayao Z et al.. “Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35759724 ↗

    L1GUIDELINECited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment
  276. [276]

    Blair VR, McLeod M, Carneiro F et al.. “Hereditary diffuse gastric cancer: updated clinical practice guidelines.” The Lancet. Oncology (2020). PMID: 32758476 ↗

    L5GUIDELINECited in: Genetics and Hereditary Predisposition, Management Overview, History and Evolution of Treatment
  277. [277]

    Geyer CE, Garber JE, Gelber RD et al.. “Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 36228963 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment
  278. [278]

    Robson ME, Tung N, Conte P et al.. “OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30689707 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  279. [279]

    Bardia A, Tolaney SM, Punie K et al.. “Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34116144 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis
  280. [280]

    Litton JK, Hurvitz SA, Mina LA et al.. “Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32828825 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition
  281. [281]

    Crimini E, Repetto M, Aftimos P et al.. “Precision medicine in breast cancer: From clinical trials to clinical practice.” Cancer treatment reviews (2021). PMID: 34049187 ↗

    L5TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  282. [282]

    Schettini F, Venturini S, Giuliano M et al.. “Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.” Cancer treatment reviews (2022). PMID: 36202026 ↗

    L1SR_OBSCited in: Genetics and Hereditary Predisposition
  283. [283]

    Ng T, Chan M, Khor CC et al.. “The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review.” Cancer treatment reviews (2014). PMID: 25458605 ↗

    L2SR_OBSCited in: Genetics and Hereditary Predisposition
  284. [284]

    Zhang B, Beeghly-Fadiel A, Long J et al.. “Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.” The Lancet. Oncology (2011). PMID: 21514219 ↗

    L3SR_OBSCited in: Genetics and Hereditary Predisposition
  285. [285]

    Morgan AJ, Giannoudis A, Palmieri C. “The genomic landscape of breast cancer brain metastases: a systematic review.” The Lancet. Oncology (2021). PMID: 33387511 ↗

    L2SR_OBSCited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis
  286. [286]

    Rowlands CF, Allen S, Balmaña J et al.. “Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38986768 ↗

    L3SR_OBSCited in: Genetics and Hereditary Predisposition
  287. [287]

    Tichy JR, Lim E, Anders CK. “Breast cancer in adolescents and young adults: a review with a focus on biology.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 24029122 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Clinical Presentation
  288. [288]

    Lyons TG, Robson ME. “Resurrection of PARP Inhibitors in Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30181424 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Staging, Prognosis and Prognostic Factors
  289. [289]

    Goncalves R, Bose R. “Using multigene tests to select treatment for early-stage breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23411384 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  290. [290]

    Reid S, Spalluto L, Pal T. “Breast Cancer Risk Stratification in Black Women: Current Status and Potential Solutions to Improve Accuracy.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671467 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  291. [291]

    Domchek SM, Stopfer JE, Rebbeck TR. “Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16451773 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  292. [292]

    Cho EH, Kim JY, Im SA et al.. “Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11).” ESMO open (2021). PMID: 34438242 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition
  293. [293]

    Loibl S, O'Shaughnessy J, Untch M et al.. “Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.” The Lancet. Oncology (2018). PMID: 29501363 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition
  294. [294]

    Li H, Liu J, Ouyang Q et al.. “Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2025). PMID: 41308673 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition
  295. [295]

    Tutt ANJ, Garber JE, Kaufman B et al.. “Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.” The New England journal of medicine (2021). PMID: 34081848 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers
  296. [296]

    Robson M, Im SA, Senkus E et al.. “Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.” The New England journal of medicine (2017). PMID: 28578601 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers
  297. [297]

    Litton JK, Rugo HS, Ettl J et al.. “Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.” The New England journal of medicine (2018). PMID: 30110579 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition
  298. [298]

    Cardoso F, van't Veer LJ, Bogaerts J et al.. “70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.” The New England journal of medicine (2016). PMID: 27557300 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition, Histopathology and Molecular Biology, Staging
  299. [299]

    Tung NM, Robson ME, Ventz S et al.. “TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 33119476 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  300. [300]

    Kaufman B, Shapira-Frommer R, Schmutzler RK et al.. “Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25366685 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors
  301. [301]

    Toss A, Blondeaux E, Tenedini E et al.. “Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41260260 ↗

    L2COHORTCited in: Genetics and Hereditary Predisposition
  302. [302]

    Chen S, Parmigiani G. “Meta-analysis of BRCA1 and BRCA2 penetrance.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17416853 ↗

    L1SR_OBSCited in: Genetics and Hereditary Predisposition
  303. [303]

    Yu KD, Ye FG, He M et al.. “Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.” JAMA oncology (2020). PMID: 32789480 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors
  304. [304]

    Boni V, Pistilli B, Braña I et al.. “Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.” ESMO open (2022). PMID: 36037567 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  305. [305]

    Ródon J, Arkenau HT, Funchain P et al.. “A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations.” ESMO open (2025). PMID: 41475241 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  306. [306]

    Van Baelen K, Geukens T, Maetens M et al.. “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35605746 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Clinical Presentation, Biopsy and Histologic Diagnosis, Prognosis and Prognostic Factors
  307. [307]

    Lynch HT, Snyder C, Casey MJ. “Hereditary ovarian and breast cancer: what have we learned?” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24131978 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  308. [308]

    Rizzolo P, Silvestri V, Tommasi S et al.. “Male breast cancer: genetics, epigenetics, and ethical aspects.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24131976 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  309. [309]

    Cooper BT, Murphy JO, Sacchini V et al.. “Local approaches to hereditary breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24131971 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  310. [310]

    Paradiso A, Formenti S. “Hereditary breast cancer: clinical features and risk reduction strategies.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21285148 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  311. [311]

    . “Olaparib Keeps Hereditary Breast Tumors in Check.” Cancer discovery (2017). PMID: 28583909 ↗

    L5TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  312. [312]

    Vora SR, Juric D, Kim N et al.. “CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.” Cancer cell (2014). PMID: 25002028 ↗

    L5TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  313. [313]

    Fasching PA, Schmatloch S, Hauke J et al.. “Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39998850 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition
  314. [314]

    Blondeaux E, Sonnenblick A, Agostinetto E et al.. “Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.” The Lancet. Oncology (2025). PMID: 40347973 ↗

    L2COHORTCited in: Genetics and Hereditary Predisposition, Clinical Presentation
  315. [315]

    Saad M, Mokrab Y, Halabi N et al.. “Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study.” The Lancet. Oncology (2022). PMID: 35150601 ↗

    L2COHORTCited in: Genetics and Hereditary Predisposition
  316. [316]

    Manchanda R, Sun L, Sobocan M et al.. “Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38866043 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  317. [317]

    Nielsen SM, Russell EM, Ellsworth RE et al.. “Utilization of Cancer Screening, Prevention, and Treatment in Women With Variants of Uncertain Significance in Breast Cancer Susceptibility Genes.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40306323 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  318. [318]

    Lynce F, Graham N, Kochupurakkal BS et al.. “A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41335237 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  319. [319]

    Guiu S, Balmaña J, Lemercier P et al.. “Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40986529 ↗

    L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  320. [320]

    Pensabene M, Calabrese A, von Arx C et al.. “Cancer genetic counselling for hereditary breast cancer in the era of precision oncology.” Cancer treatment reviews (2024). PMID: 38452709 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Clinical Presentation, Management Overview
  321. [321]

    Blondeaux E, Arecco L, Punie K et al.. “Germline TP53 pathogenic variants and breast cancer: A narrative review.” Cancer treatment reviews (2023). PMID: 36739824 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  322. [322]

    Economopoulou P, Dimitriadis G, Psyrri A. “Beyond BRCA: new hereditary breast cancer susceptibility genes.” Cancer treatment reviews (2014). PMID: 25467110 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment
  323. [323]

    Lambertini M, Goldrat O, Toss A et al.. “Fertility and pregnancy issues in BRCA-mutated breast cancer patients.” Cancer treatment reviews (2017). PMID: 28750297 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Clinical Presentation, Special Populations
  324. [324]

    Serpico D, Molino L, Di Cosimo S. “microRNAs in breast cancer development and treatment.” Cancer treatment reviews (2013). PMID: 24286642 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors, Special Populations
  325. [325]

    Kamaraju S, Conroy M, Harris A et al.. “Challenges to genetic testing for germline mutations associated with breast cancer among African Americans.” Cancer treatment reviews (2024). PMID: 38325071 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  326. [326]

    Amir E, Seruga B, Serrano R et al.. “Targeting DNA repair in breast cancer: a clinical and translational update.” Cancer treatment reviews (2010). PMID: 20385443 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  327. [327]

    Yap YS. “Outcomes in breast cancer-does ethnicity matter?” ESMO open (2023). PMID: 37290358 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Clinical Presentation
  328. [328]

    Mazzeo R, Sears J, Palmero L et al.. “Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology.” ESMO open (2024). PMID: 39288656 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis
  329. [329]

    Loong HH, Shimizu T, Prawira A et al.. “Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.” ESMO open (2023). PMID: 37356359 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  330. [330]

    Huntley C, Torr B, Sud A et al.. “Utility of polygenic risk scores in UK cancer screening: a modelling analysis.” The Lancet. Oncology (2023). PMID: 37178708 ↗

    L2REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  331. [331]

    Brewster AM, Chavez-MacGregor M, Brown P. “Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.” The Lancet. Oncology (2014). PMID: 25456381 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  332. [332]

    Even-Sapir E, Inbar M. “PET in women with high risk for breast or ovarian cancer.” The Lancet. Oncology (2010). PMID: 20615754 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Imaging
  333. [333]

    D'Andrea AD. “Susceptibility pathways in Fanconi's anemia and breast cancer.” The New England journal of medicine (2010). PMID: 20484397 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  334. [334]

    Khan S, Fagerholm R, Rafiq S et al.. “Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25964295 ↗

    L2SR_OBSCited in: Genetics and Hereditary Predisposition
  335. [335]

    Morganti S, Marra A, De Angelis C et al.. “PARP Inhibitors for Breast Cancer Treatment: A Review.” JAMA oncology (2024). PMID: 38512229 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Management Overview, Prognosis and Prognostic Factors
  336. [336]

    Tarantino P, Hortobagyi G, Tolaney SM et al.. “Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review.” JAMA oncology (2024). PMID: 39264638 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  337. [337]

    Moasser MM, Krop IE. “The Evolving Landscape of HER2 Targeting in Breast Cancer.” JAMA oncology (2015). PMID: 26204261 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  338. [338]

    Moser SC, Jonkers J. “Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.” Cancer discovery (2025). PMID: 40025950 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment
  339. [339]

    Alix-Panabières C, Pantel K. “Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.” Cancer discovery (2016). PMID: 26969689 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis, Prognosis and Prognostic Factors
  340. [340]

    Liang H. “More reliable breast cancer risk assessment for every woman.” Cancer cell (2021). PMID: 33740422 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  341. [341]

    Seefat RL, Vliek SB, de Jong VMT et al.. “Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2026). PMID: 42372741 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  342. [342]

    Bhattacharyya S, Thomas JV, Prasad A et al.. “Genomic landscape of triple-negative breast cancer in South Asian populations: a systematic review.” BMC cancer (2026). PMID: 42402565 ↗

    L2SR_OBSCited in: Genetics and Hereditary Predisposition
  343. [343]

    Li S, Silvestri V, Leslie G et al.. “Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35077220 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  344. [344]

    Bougeard G, Renaux-Petel M, Flaman JM et al.. “Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26014290 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation
  345. [345]

    Yadav S, Boddicker NJ, Na J et al.. “Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36623243 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation
  346. [346]

    Couch FJ, Hart SN, Sharma P et al.. “Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25452441 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation
  347. [347]

    Espenschied CR, LaDuca H, Li S et al.. “Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28514183 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition
  348. [348]

    Garcia-Closas M, Chanock S. “Genetic susceptibility loci for breast cancer by estrogen receptor status.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 19088016 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  349. [349]

    Gorski JJ, Kennedy RD, Hosey AM et al.. “The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19223511 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  350. [350]

    Lee KL, Yam C, Zhao L et al.. “Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial.” Breast cancer research and treatment (2026). PMID: 42223695 ↗

    L2TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
  351. [351]

    Sawyer SL, Tian L, Kähkönen M et al.. “Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.” Cancer discovery (2014). PMID: 25472942 ↗

    L4CASE_REPORTCited in: Genetics and Hereditary Predisposition
  352. [352]

    Katz ML, Schnell PM, Reiter PL et al.. “Knowledge of cancer genetics and attitudes about genetic counseling and testing: a randomized trial of the Know Your Risk intervention compared to conventional genetic counseling.” Cancer causes & control : CCC (2026). PMID: 42377622 ↗

    L1RCTCited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment
  353. [353]

    Luo WS, Shi A, Wang Z et al.. “Association between ERCC5 gene rs17655 polymorphism and the risk of breast cancer: an updated meta-analysis.” Environmental health and preventive medicine (2026). PMID: 42386575 ↗

    L1SR_OBSCited in: Genetics and Hereditary Predisposition
  354. [354]

    Rodriguez-Hernandez A, Martínez-Sáez O, Brasó-Maristany F et al.. “Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study.” ESMO open (2025). PMID: 40209283 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition
  355. [355]

    Agostinetto E, Bruzzone M, Hamy AS et al.. “Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.” ESMO open (2024). PMID: 39288653 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition, Histopathology and Molecular Biology
  356. [356]

    Sánchez-Bayona R, de Nicolás-Hernández J, Saura C et al.. “Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.” ESMO open (2026). PMID: 42114485 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  357. [357]

    Perachino M, Blondeaux E, Delucchi V et al.. “Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers.” ESMO open (2025). PMID: 40811881 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  358. [358]

    Incorvaia L, Marchetti C, Brando C et al.. “BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study.” ESMO open (2025). PMID: 39847877 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  359. [359]

    Dorling L, Carvalho S, Allen J et al.. “Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.” The New England journal of medicine (2021). PMID: 33471991 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition
  360. [360]

    Antoniou AC, Casadei S, Heikkinen T et al.. “Breast-cancer risk in families with mutations in PALB2.” The New England journal of medicine (2014). PMID: 25099575 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  361. [361]

    Patocs A, Zhang L, Xu Y et al.. “Breast-cancer stromal cells with TP53 mutations and nodal metastases.” The New England journal of medicine (2007). PMID: 18094375 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  362. [362]

    Shen X, Yang J, Du Y et al.. “Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review.” Frontiers in immunology (2026). PMID: 42327776 ↗

    L4CASE_REPORTCited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis, Imaging
  363. [363]

    Bychkovsky BL, Agaoglu NB, Horton C et al.. “Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.” JAMA oncology (2022). PMID: 36136322 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation
  364. [364]

    Rodriguez J, Grassmann F, Xiao Q et al.. “Investigation of Genetic Alterations Associated With Interval Breast Cancer.” JAMA oncology (2024). PMID: 38270937 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition
  365. [365]

    Couch FJ, Shimelis H, Hu C et al.. “Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.” JAMA oncology (2017). PMID: 28418444 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition
  366. [366]

    . “Tumor Profiling: Adding Proteomics to Genomics.” Cancer discovery (2016). PMID: 27354270 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  367. [367]

    . “Metastatic ER+ Breast Cancer's Genomic Landscape.” Cancer discovery (2016). PMID: 27974416 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition
  368. [368]

    . “PROMPT to detail breast cancer risk.” Cancer discovery (2014). PMID: 25477092 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  369. [369]

    Park DJ, Tao K, Le Calvez-Kelm F et al.. “Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers.” Cancer discovery (2014). PMID: 25050558 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition
  370. [370]

    . “Breast cancer susceptibility genes pile up.” Cancer discovery (2015). PMID: 25851858 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  371. [371]

    . “First PARP Inhibitor Ok'd for Breast Cancer.” Cancer discovery (2018). PMID: 29382645 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  372. [372]

    Lin CJ, Jin X, Ma D et al.. “Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.” Cancer cell (2024). PMID: 38593782 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors
  373. [373]

    Berger AC, Korkut A, Kanchi RS et al.. “A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.” Cancer cell (2018). PMID: 29622464 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors
  374. [374]

    Walsh T, King MC. “Ten genes for inherited breast cancer.” Cancer cell (2007). PMID: 17292821 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  375. [375]

    Drost R, Bouwman P, Rottenberg S et al.. “BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.” Cancer cell (2011). PMID: 22172724 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  376. [376]

    Knappskog S, Bjørnslett M, Myklebust LM et al.. “The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.” Cancer cell (2011). PMID: 21316605 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation
  377. [377]

    Wan L, Lu X, Yuan S et al.. “MTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors.” Cancer cell (2014). PMID: 24981741 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  378. [378]

    Nevins JR. “New breast cancer genes-discovery at the intersection of complex data sets.” Cancer cell (2007). PMID: 18068627 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  379. [379]

    Le J, Madlensky L, Retson TA et al.. “Genetics, Screening, and Risk-reducing Interventions for Breast Cancer.” The Surgical clinics of North America (2026). PMID: 42419307 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  380. [380]

    Etessami JD, Dalla Via G, Ferraro E et al.. “Treatment of breast cancer brain metastases in the era of novel drugs.” Cancer treatment reviews (2026). PMID: 42372577 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  381. [381]

    McDermott E, Khalili K, Kim TK et al.. “Stomach and beyond: imaging the linitis plastica phenotype in signet ring cell carcinoma.” Abdominal radiology (New York) (2026). PMID: 42360344 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  382. [382]

    Robaczyńska J, Kiljańczyk M, Maj M et al.. “The Potential Role of Vitamin D in BRCA1 Pathogenic Variant Carriers: A Narrative Review.” International journal of molecular sciences (2026). PMID: 42353259 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  383. [383]

    Widschwendter M, Schmutzler R, Pashayan N et al.. “Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.” NPJ breast cancer (2026). PMID: 42350451 ↗

    L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
  384. [384]

    Rodriguez J, Grassmann F, Kaukonen D et al.. “Blood DNA methylation and breast cancer risk: a prospective nested case-control study.” EBioMedicine (2026). PMID: 42349257 ↗

    L3CASE_CONTROLCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers
  385. [385]

    Sun J, Meng H, Yao L et al.. “Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28724667 ↗

    L4OTHERCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
  386. [386]

    Hanenberg H, Zhang F, Malev N et al.. “Reclassification of ATM Missense Variants of Uncertain Significance by Integrating Results from Systematic Functional Assays into an ACMG Points-Based Framework.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40105422 ↗

    L5OTHERCited in: Genetics and Hereditary Predisposition
  387. [387]

    Turner NC, Balmaña J, Poncet C et al.. “Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34301749 ↗

    L1OTHERCited in: Genetics and Hereditary Predisposition
  388. [388]

    Waks AG, Kim D, Jain E et al.. “Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35101884 ↗

    L2OTHERCited in: Genetics and Hereditary Predisposition
  389. [389]

    Huang H, Couch RE, Karam R et al.. “Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39513960 ↗

    L3OTHERCited in: Genetics and Hereditary Predisposition
  390. [390]

    Jhaveri K, Eli LD, Wildiers H et al.. “Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37597578 ↗

    L2RCTCited in: Histopathology and Molecular Biology
  391. [391]

    Huppert LA, Wolf D, Yau C et al.. “Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39477071 ↗

    L1RCTCited in: Histopathology and Molecular Biology, Staging
  392. [392]

    Houssami N, Ciatto S, Macaskill P et al.. “Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18474876 ↗

    L1SR_OBSCited in: Histopathology and Molecular Biology
  393. [393]

    Yang JT, Wijetunga NA, Pentsova E et al.. “Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35802849 ↗

    L1RCTCited in: Histopathology and Molecular Biology
  394. [394]

    Zhang H, Zhang N, Moran MS et al.. “Special subtypes with favorable prognosis in breast cancer: A registry-based cohort study and network meta-analysis.” Cancer treatment reviews (2020). PMID: 33075683 ↗

    L2SR_OBSCited in: Histopathology and Molecular Biology, Special Populations
  395. [395]

    Trapani D, Gandini S, Corti C et al.. “Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis.” Cancer treatment reviews (2021). PMID: 33878560 ↗

    L1SR_OBSCited in: Histopathology and Molecular Biology
  396. [396]

    Blok EJ, Bastiaannet E, van den Hout WB et al.. “Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe.” Cancer treatment reviews (2017). PMID: 29175678 ↗

    L2SR_OBSCited in: Histopathology and Molecular Biology
  397. [397]

    Costa R, Gill N, Rademaker AW et al.. “Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis.” Cancer treatment reviews (2017). PMID: 28279895 ↗

    L2SR_OBSCited in: Histopathology and Molecular Biology
  398. [398]

    Matikas A, Zerdes I, Lövrot J et al.. “PD-1 protein and gene expression as prognostic factors in early breast cancer.” ESMO open (2020). PMID: 33172959 ↗

    L2SR_OBSCited in: Histopathology and Molecular Biology, Prognosis and Prognostic Factors
  399. [399]

    Chatterji S, Krzoska E, Thoroughgood CW et al.. “Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.” The Lancet. Oncology (2023). PMID: 36725152 ↗

    L2SR_OBSCited in: Histopathology and Molecular Biology
  400. [400]

    Huober J, Gelber S, Goldhirsch A et al.. “Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22707751 ↗

    L2SR_OBSCited in: Histopathology and Molecular Biology, Staging
  401. [401]

    Ellis M. “Genomic analysis of breast cancer heralds a changing treatment paradigm.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24853210 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Clinical Presentation
  402. [402]

    Im SA, Park K, Koh J et al.. “Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21).” ESMO open (2025). PMID: 40997746 ↗

    L1RCTCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
  403. [403]

    Piccart M, van 't Veer LJ, Poncet C et al.. “70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.” The Lancet. Oncology (2021). PMID: 33721561 ↗

    L1RCTCited in: Histopathology and Molecular Biology
  404. [404]

    Abdel-Fatah TMA, Agarwal D, Liu DX et al.. “SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.” The Lancet. Oncology (2016). PMID: 27312051 ↗

    L2RCTCited in: Histopathology and Molecular Biology
  405. [405]

    Sparano JA, Gray RJ, Makower DF et al.. “Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.” The New England journal of medicine (2015). PMID: 26412349 ↗

    L2RCTCited in: Histopathology and Molecular Biology
  406. [406]

    Yang JT, Yerramilli D, Pentsova E et al.. “Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial.” JAMA oncology (2025). PMID: 40906462 ↗

    L1RCTCited in: Histopathology and Molecular Biology
  407. [407]

    Esserman LJ, Yau C, Thompson CK et al.. “Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.” JAMA oncology (2017). PMID: 28662222 ↗

    L2RCTCited in: Histopathology and Molecular Biology
  408. [408]

    Sestak I, Buus R, Cuzick J et al.. “Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.” JAMA oncology (2018). PMID: 29450494 ↗

    L2RCTCited in: Histopathology and Molecular Biology
  409. [409]

    Denkert C, Rachakonda S, Karn T et al.. “Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.” Cancer cell (2025). PMID: 39933898 ↗

    L2RCTCited in: Histopathology and Molecular Biology, History and Evolution of Treatment, Prognosis and Prognostic Factors
  410. [410]

    Konstantinopoulos PA, Barry WT, Birrer M et al.. “Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.” The Lancet. Oncology (2019). PMID: 30880072 ↗

    L4TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
  411. [411]

    Bochtler T, Endris V, Reiling A et al.. “Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29891518 ↗

    L4CASE_REPORTCited in: Histopathology and Molecular Biology
  412. [412]

    Reeves GK, Beral V, Green J et al.. “Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis.” The Lancet. Oncology (2006). PMID: 17081916 ↗

    L2SR_OBSCited in: Histopathology and Molecular Biology
  413. [413]

    Matikas A, Zerdes I, Lövrot J et al.. “Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31227501 ↗

    L1SR_OBSCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
  414. [414]

    Piccart-Gebhart MJ, Sotiriou C. “Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 18083699 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  415. [415]

    Maur M, Guarneri V, Frassoldati A et al.. “Primary systemic therapy in operable breast cancer: clinical data and biological fall-out.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16807447 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  416. [416]

    Matikas A, Foukakis T, Swain S et al.. “Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31131397 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  417. [417]

    Fasano J, Muggia F. “Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19150941 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  418. [418]

    Dugo M, Huang CS, Egle D et al.. “The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39308141 ↗

    L2RCTCited in: Histopathology and Molecular Biology
  419. [419]

    Kennecke HF, Speers CH, Ennis CA et al.. “Impact of routine pathology review on treatment for node-negative breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22564990 ↗

    L2REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  420. [420]

    Kamath SD, Kircher SM, Benson AB. “Comparison of Cancer Burden and Nonprofit Organization Funding Reveals Disparities in Funding Across Cancer Types.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31319386 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  421. [421]

    Rediti M, Fimereli D, Mileva M et al.. “Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39470686 ↗

    L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology, Imaging
  422. [422]

    Peters S, Meyer ML, André F et al.. “Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.” ESMO open (2026). PMID: 42431135 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  423. [423]

    Corso G, Shen S, Criscitiello C et al.. “Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group.” Cancer treatment reviews (2025). PMID: 40815983 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Clinical Presentation, Imaging
  424. [424]

    Nguyen NP, Almeida FS, Chi A et al.. “Molecular biology of breast cancer stem cells: potential clinical applications.” Cancer treatment reviews (2010). PMID: 20231058 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  425. [425]

    Eroles P, Bosch A, Pérez-Fidalgo JA et al.. “Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.” Cancer treatment reviews (2011). PMID: 22178455 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  426. [426]

    Wood SL, Westbrook JA, Brown JE. “Omic-profiling in breast cancer metastasis to bone: implications for mechanisms, biomarkers and treatment.” Cancer treatment reviews (2013). PMID: 23958309 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  427. [427]

    Garufi G, Carbognin L, Arcanà C et al.. “Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?” Cancer treatment reviews (2022). PMID: 35987149 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  428. [428]

    Griguolo G, Bottosso M, Vernaci G et al.. “Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available evidence and clinical implications.” Cancer treatment reviews (2021). PMID: 34896969 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  429. [429]

    Sonnenblick A, Fumagalli D, Sotiriou C et al.. “Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?” Cancer treatment reviews (2014). PMID: 25151406 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Imaging
  430. [430]

    Fernández Y, Cueva J, Palomo AG et al.. “Novel therapeutic approaches to the treatment of metastatic breast cancer.” Cancer treatment reviews (2009). PMID: 19883980 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  431. [431]

    Saijo N. “Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.” Cancer treatment reviews (2011). PMID: 21652149 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  432. [432]

    Oakman C, Moretti E, Galardi F et al.. “The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.” Cancer treatment reviews (2009). PMID: 19758759 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  433. [433]

    De P, Miskimins K, Dey N et al.. “Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope.” Cancer treatment reviews (2013). PMID: 23352077 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  434. [434]

    Desmedt C, Haibe-Kains B, Wirapati P et al.. “Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18698033 ↗

    L5SR_OBSCited in: Histopathology and Molecular Biology
  435. [435]

    Stover DG, Coloff JL, Barry WT et al.. “The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27330058 ↗

    L5SR_OBSCited in: Histopathology and Molecular Biology
  436. [436]

    Waldron L, Ogino S, Hoshida Y et al.. “Expression profiling of archival tumors for long-term health studies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 23136189 ↗

    L5SR_OBSCited in: Histopathology and Molecular Biology
  437. [437]

    Kono M, Fujii T, Lim B et al.. “Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.” JAMA oncology (2017). PMID: 28301631 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  438. [438]

    Curigliano G, Burstein HJ, Gnant M et al.. “Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37683978 ↗

    L1OTHERCited in: Histopathology and Molecular Biology, Management Overview
  439. [439]

    Tetzlaff MT, Messina JL, Stein JE et al.. “Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29945191 ↗

    L1OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
  440. [440]

    Cantore T, Hoang DT, Pal LR et al.. “Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 42203036 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  441. [441]

    Bareche Y, Venet D, Ignatiadis M et al.. “Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29365031 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  442. [442]

    Li J, Holm J, Bergh J et al.. “Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25488685 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  443. [443]

    Viale G. “The current state of breast cancer classification.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22987963 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  444. [444]

    Korde LA, Somerfield MR, Carey LA et al.. “Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33507815 ↗

    L1OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Management Overview
  445. [445]

    Massarweh SA, Sledge GW, Miller DP et al.. “Molecular Characterization and Mortality From Breast Cancer in Men.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29584547 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  446. [446]

    Korde LA, Zujewski JA, Kamin L et al.. “Multidisciplinary meeting on male breast cancer: summary and research recommendations.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20308661 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  447. [447]

    Micheli A, Meneghini E, Secreto G et al.. “Plasma testosterone and prognosis of postmenopausal breast cancer patients.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17548841 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  448. [448]

    Beitsch PD, Whitworth PW, Hughes K et al.. “Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30526229 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  449. [449]

    Mandelker D, Marra A, Zheng-Lin B et al.. “Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37607324 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  450. [450]

    McKian KP, Reynolds CA, Visscher DW et al.. “Novel breast tissue feature strongly associated with risk of breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19805686 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  451. [451]

    Plichta JK, Thomas SM, Hayes DF et al.. “Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36944149 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Imaging
  452. [452]

    Holowatyj AN, Cote ML, Ruterbusch JJ et al.. “Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29341832 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  453. [453]

    Climent J, Perez-Losada J, Quigley DA et al.. “Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20625127 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  454. [454]

    King TA, Pilewskie M, Muhsen S et al.. “Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26371145 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  455. [455]

    Mayer IA, Abramson VG, Lehmann BD et al.. “New strategies for triple-negative breast cancer--deciphering the heterogeneity.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24536073 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  456. [456]

    Gingras I, Desmedt C, Ignatiadis M et al.. “CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer--Where Did It Start and Where Are We Now?” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26527804 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  457. [457]

    Brandt B, Meyer-Staeckling S, Schmidt H et al.. “Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17189396 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  458. [458]

    Sinberger LA, Zahavi T, Keren-Khadmy N et al.. “Refining prognostic tools for luminal breast cancer: genetic insights and comprehensive analysis.” ESMO open (2025). PMID: 40305907 ↗

    L3OTHERCited in: Histopathology and Molecular Biology, Prognosis and Prognostic Factors
  459. [459]

    Li L, Yin G, Liu X et al.. “Genomic and transcriptomic evaluation of primary and recurrent luminal B-like breast cancer.” ESMO open (2026). PMID: 42263480 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  460. [460]

    Karlsson A, Ellonen A, Irjala H et al.. “Impact of deep learning-determined smoking status on mortality of cancer patients: never too late to quit.” ESMO open (2021). PMID: 34091262 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  461. [461]

    Chiodoni C, Sangaletti S, Lecchi M et al.. “A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer.” ESMO open (2023). PMID: 37393630 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  462. [462]

    Carausu M, Carton M, Darlix A et al.. “Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database.” ESMO open (2021). PMID: 33984675 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  463. [463]

    Fan Y, Wang Y, He L et al.. “Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.” ESMO open (2021). PMID: 34392135 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Imaging, Staging
  464. [464]

    Nakayama I, Takahari D, Chin K et al.. “Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.” ESMO open (2023). PMID: 37348349 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  465. [465]

    Hibino Y, Ito M, Satake T et al.. “Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis.” ESMO open (2021). PMID: 34118770 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  466. [466]

    Garcia-Pelaez J, Barbosa-Matos R, Lobo S et al.. “Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes.” The Lancet. Oncology (2022). PMID: 36436516 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  467. [467]

    Scott JG, Berglund A, Schell MJ et al.. “A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.” The Lancet. Oncology (2016). PMID: 27993569 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  468. [468]

    Gao JJ, Cheng J, Bloomquist E et al.. “CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.” The Lancet. Oncology (2019). PMID: 31859246 ↗

    L1OTHERCited in: Histopathology and Molecular Biology
  469. [469]

    Ciatto S, Houssami N, Bernardi D et al.. “Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study.” The Lancet. Oncology (2013). PMID: 23623721 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  470. [470]

    Fan C, Oh DS, Wessels L et al.. “Concordance among gene-expression-based predictors for breast cancer.” The New England journal of medicine (2006). PMID: 16899776 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  471. [471]

    Rafaelian A, Schneider M, Dubinski D et al.. “Impact of infratentorial location on survival after surgical resection of brain metastases: a multicenter retrospective study.” Neuro-oncology advances (2026). PMID: 42325607 ↗

    L2COHORTCited in: Histopathology and Molecular Biology
  472. [472]

    Fernandez-Martinez A, Rediti M, Tang G et al.. “Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.” JAMA oncology (2024). PMID: 38546612 ↗

    L1OTHERCited in: Histopathology and Molecular Biology, Staging
  473. [473]

    Spratt DE, Chan T, Waldron L et al.. “Racial/Ethnic Disparities in Genomic Sequencing.” JAMA oncology (2016). PMID: 27366979 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  474. [474]

    Peiffer DS, Zhao F, Chen N et al.. “Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.” JAMA oncology (2023). PMID: 36821125 ↗

    L2OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis, Staging
  475. [475]

    Fernandez-Martinez A, Pascual T, Singh B et al.. “Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.” JAMA oncology (2023). PMID: 36602784 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  476. [476]

    Tsai M, Lo S, Audeh W et al.. “Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.” JAMA oncology (2018). PMID: 29075751 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  477. [477]

    Bose R, Kavuri SM, Searleman AC et al.. “Activating HER2 mutations in HER2 gene amplification negative breast cancer.” Cancer discovery (2012). PMID: 23220880 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
  478. [478]

    Hamilton AM, Hoadley KA, Troester MA. “Race and Ancestry in Immune Response to Breast Cancer.” Cancer discovery (2022). PMID: 36321309 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  479. [479]

    Oudin MJ, Jonas O, Kosciuk T et al.. “Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.” Cancer discovery (2016). PMID: 26811325 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  480. [480]

    Hu Y, Petit SA, Ficarro SB et al.. “PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.” Cancer discovery (2014). PMID: 25252691 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  481. [481]

    Werner S, Brors B, Eick J et al.. “Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2.” Cancer discovery (2015). PMID: 25716347 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  482. [482]

    Miller TW, Balko JM, Fox EM et al.. “ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.” Cancer discovery (2011). PMID: 22049316 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  483. [483]

    Novitskiy SV, Pickup MW, Gorska AE et al.. “TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.” Cancer discovery (2011). PMID: 22408746 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  484. [484]

    Cassetta L, Fragkogianni S, Sims AH et al.. “Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets.” Cancer cell (2019). PMID: 30930117 ↗

    L3OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Management Overview
  485. [485]

    Dhimolea E, de Matos Simoes R, Kansara D et al.. “An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence.” Cancer cell (2021). PMID: 33417832 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  486. [486]

    Melo SA, Sugimoto H, O'Connell JT et al.. “Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis.” Cancer cell (2014). PMID: 25446899 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  487. [487]

    Edgren H, Kallioniemi O. “Integrated breast cancer genomics.” Cancer cell (2006). PMID: 17157784 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Clinical Presentation
  488. [488]

    Chin K, DeVries S, Fridlyand J et al.. “Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.” Cancer cell (2006). PMID: 17157792 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  489. [489]

    Shan L, Zhou X, Liu X et al.. “FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic Response and Breast Cancer Carcinogenesis.” Cancer cell (2016). PMID: 27773593 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  490. [490]

    Hinohara K, Wu HJ, Vigneau S et al.. “KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.” Cancer cell (2018). PMID: 30472020 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  491. [491]

    Rios AC, Capaldo BD, Vaillant F et al.. “Intraclonal Plasticity in Mammary Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging.” Cancer cell (2019). PMID: 30930118 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  492. [492]

    Downes M, Evans RM. “Staying the distance: avoiding the proteasomal trap.” Cancer cell (2008). PMID: 18328421 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  493. [493]

    Tu WB, Shiah YJ, Lourenco C et al.. “MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.” Cancer cell (2018). PMID: 30300580 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  494. [494]

    Chang CJ, Yang JY, Xia W et al.. “EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.” Cancer cell (2011). PMID: 21215703 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  495. [495]

    Evdokimova V, Tognon C, Ng T et al.. “Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition.” Cancer cell (2009). PMID: 19411069 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  496. [496]

    Wu X, Ye X, Chen H et al.. “The translational roles of circular RNAs in cancers and their underlying molecular mechanisms.” Medical oncology (Northwood, London, England) (2026). PMID: 42363998 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  497. [497]

    Burstein MD, Tsimelzon A, Poage GM et al.. “Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25208879 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  498. [498]

    Jovanović B, Church SE, Gorman KM et al.. “Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39136550 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  499. [499]

    Nik-Zainal S, Morganella S. “Mutational Signatures in Breast Cancer: The Problem at the DNA Level.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28572256 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  500. [500]

    Akcakanat A, Zheng X, Cruz Pico CX et al.. “Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33782032 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  501. [501]

    Georgescu TA, Georgescu AC, Olinca MV. “When Breast Cancer Meets the Uterus: A Quantitative Review of 105 Cases Spanning Four Decades.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356217 ↗

    L4REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
  502. [502]

    Hou W. “The Emerging Role of CACNA1E in Cancer: Molecular Mechanisms and Therapeutic Implications.” Journal of Cancer (2026). PMID: 42327581 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  503. [503]

    Basheeruddin M, Qausain S, Anjankar A et al.. “Advancements in cancer biomarker discovery over fifteen years: diagnostics and prognostic approach in somatic cancer.” Oncology reviews (2026). PMID: 42181045 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  504. [504]

    Huang S, Westvold SJ, Soulos PR et al.. “Tumor characteristics associated with tomosynthesis versus digital mammography in older women with screen-detected breast cancer.” Breast cancer research and treatment (2026). PMID: 42420682 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  505. [505]

    Namoglu EC, Flanagan MR, Teles MS et al.. “Omission of sentinel lymph node biopsy among women age 50-70 with early-stage breast cancer: applying an updated ASCO Guideline to a real-world population.” Practical radiation oncology (2026). PMID: 42409317 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  506. [506]

    Abeles E, Shui AM, Quirarte A et al.. “Omission of Axillary Surgery in Patients with Invasive Lobular Carcinoma of the Breast: Rates of Nodal Involvement in Clinically Node Negative Patients and Impact on Recurrence in a Single Institution Analysis.” Annals of surgical oncology (2026). PMID: 42406219 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  507. [507]

    Pereira A, Kaser S, Varga Z et al.. “3D virtual histopathology of human breast tissues using an X-ray grating interferometry micro CT system.” Experimental and molecular pathology (2026). PMID: 42378867 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  508. [508]

    Hagenaars SC, Hueting TA, Dieleman F et al.. “Added value of the tumor-stroma ratio to the PREDICT model for breast cancer.” Breast (Edinburgh, Scotland) (2026). PMID: 42372582 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  509. [509]

    Cheng M, Li X, Song N et al.. “The YAP-TEAD4 inhibitor M511-0965 suppresses triple-negative breast cancer progression by downregulating TGFB2.” Translational oncology (2026). PMID: 42365824 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  510. [510]

    Wang Y, Xie Y, Ye Y et al.. “Prognosis and Immunotherapy Effect of Triple-Negative Breast Cancer by Lactylation-Related Genes and Experimental Validation.” Oncology research (2026). PMID: 42358833 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  511. [511]

    Metcalfe K, Narod SA, Poll A et al.. “Frequency of germline pathogenic variants in breast cancer predisposing genes in a national cohort of young women with breast cancer.” British journal of cancer (2026). PMID: 42337046 ↗

    L2OTHERCited in: Histopathology and Molecular Biology
  512. [512]

    Lu X, Xie D, Cui L et al.. “FLASH radiotherapy preserves hepatic function and maintains metabolic homeostasis in a murine breast cancer model: an experimental preclinical study.” Radiation oncology (London, England) (2026). PMID: 42321761 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  513. [513]

    Viart NM, Thibault L, Lazard T et al.. “Deep learning analysis of breast cancer histology predicts ATM pathogenic variant carrier status.” NPJ digital medicine (2026). PMID: 42298170 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  514. [514]

    Azizy A, Dogan I, Yucel S et al.. “Effect of Primary Breast Surgery on Prognosis in Breast Cancer Patients Presenting with Isolated Bone Metastases.” Cancers (2026). PMID: 42279343 ↗

    L3OTHERCited in: Histopathology and Molecular Biology
  515. [515]

    Tchurikov NA, Klushevskaya ES, Lukicheva VN et al.. “Highly Aggressive and Metastatic MDA-MB-231 and Mel Z Cancer Cells Have Common Sets of Down- and Upregulated Genes During Formation of the Vasculogenic Mimicry Phenotype.” International journal of molecular sciences (2026). PMID: 42278478 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  516. [516]

    Tarantino P, Viale G, Press MF et al.. “ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37269905 ↗

    L5GUIDELINECited in: Clinical Presentation, Management Overview, History and Evolution of Treatment
  517. [517]

    Burstein HJ, Curigliano G, Thürlimann B et al.. “Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34242744 ↗

    L5GUIDELINECited in: Clinical Presentation, Management Overview
  518. [518]

    Gradishar W, Salerno KE. “NCCN Guidelines Update: Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27226503 ↗

    L1GUIDELINECited in: Clinical Presentation, Management Overview, History and Evolution of Treatment
  519. [519]

    Oktay K, Harvey BE, Partridge AH et al.. “Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29620997 ↗

    L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment, Special Populations
  520. [520]

    Su HI, Lacchetti C, Letourneau J et al.. “Fertility Preservation in People With Cancer: ASCO Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40106739 ↗

    L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment, Special Populations
  521. [521]

    Sakai H, Tsurutani J, Ozaki Y et al.. “A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B).” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39284382 ↗

    L1RCTCited in: Clinical Presentation
  522. [522]

    Lambertini M, Blondeaux E, Bruzzone M et al.. “Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34197218 ↗

    L2SR_OBSCited in: Clinical Presentation, Special Populations
  523. [523]

    Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W et al.. “Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29356607 ↗

    L1RCTCited in: Clinical Presentation
  524. [524]

    Jardel P, Sauerwein W, Olivier T et al.. “Management of choroidal metastases.” Cancer treatment reviews (2014). PMID: 25451606 ↗

    L2SR_OBSCited in: Clinical Presentation, Imaging, Prognosis and Prognostic Factors
  525. [525]

    Gradishar WJ. “Treatment of metastatic breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24853211 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview
  526. [526]

    Thomas PS. “Diagnosis and Management of High-Risk Breast Lesions.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30442737 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Prognosis and Prognostic Factors
  527. [527]

    Waks AG, Partridge AH. “Fertility Preservation in Patients With Breast Cancer: Necessity, Methods, and Safety.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 26957619 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  528. [528]

    Ligibel JA. “Role of adjuvant and posttreatment exercise programs in breast health.” Journal of the National Comprehensive Cancer Network : JNCCN (2011). PMID: 21310846 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  529. [529]

    Johnston SRD, Toi M, O'Shaughnessy J et al.. “Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.” The Lancet. Oncology (2022). PMID: 36493792 ↗

    L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  530. [530]

    Hurvitz SA, Martin M, Symmans WF et al.. “Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.” The Lancet. Oncology (2017). PMID: 29175149 ↗

    L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Staging
  531. [531]

    Diéras V, Miles D, Verma S et al.. “Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.” The Lancet. Oncology (2017). PMID: 28526536 ↗

    L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Special Populations
  532. [532]

    Bajpai J, Kapu V, Rath S et al.. “Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2024). PMID: 38224701 ↗

    L1RCTCited in: Clinical Presentation
  533. [533]

    Winer EP, Lipatov O, Im SA et al.. “Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.” The Lancet. Oncology (2021). PMID: 33676601 ↗

    L1RCTCited in: Clinical Presentation
  534. [534]

    André F, Ciruelos E, Rubovszky G et al.. “Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.” The New England journal of medicine (2019). PMID: 31091374 ↗

    L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
  535. [535]

    von Minckwitz G, Procter M, de Azambuja E et al.. “Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.” The New England journal of medicine (2017). PMID: 28581356 ↗

    L1RCTCited in: Clinical Presentation
  536. [536]

    Murthy RK, Loi S, Okines A et al.. “Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.” The New England journal of medicine (2019). PMID: 31825569 ↗

    L1RCTCited in: Clinical Presentation
  537. [537]

    Cardoso F, Parke S, Brennan DJ et al.. “Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.” The New England journal of medicine (2025). PMID: 40454634 ↗

    L1RCTCited in: Clinical Presentation
  538. [538]

    Davis SR, Moreau M, Kroll R et al.. “Testosterone for low libido in postmenopausal women not taking estrogen.” The New England journal of medicine (2008). PMID: 18987368 ↗

    L1RCTCited in: Clinical Presentation
  539. [539]

    Benitez Fuentes JD, Morgan E, de Luna Aguilar A et al.. “Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis.” JAMA oncology (2024). PMID: 37943547 ↗

    L2SR_OBSCited in: Clinical Presentation, Staging, Prognosis and Prognostic Factors
  540. [540]

    Llombart-Cussac A, Pérez-García JM, Bellet M et al.. “Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.” JAMA oncology (2021). PMID: 34617955 ↗

    L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  541. [541]

    Choi W, Porten S, Kim S et al.. “Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.” Cancer cell (2014). PMID: 24525232 ↗

    L2RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  542. [542]

    Galimberti V, Cole BF, Viale G et al.. “Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.” The Lancet. Oncology (2018). PMID: 30196031 ↗

    L1TRIAL_NONRANDOMCited in: Clinical Presentation, Biopsy and Histologic Diagnosis
  543. [543]

    Bardia A, Mayer IA, Vahdat LT et al.. “Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.” The New England journal of medicine (2019). PMID: 30786188 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation
  544. [544]

    Lehman CD, Gatsonis C, Kuhl CK et al.. “MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer.” The New England journal of medicine (2007). PMID: 17392300 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Imaging
  545. [545]

    Dogan BE, Turnbull LW. “Imaging of triple-negative breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23012298 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging
  546. [546]

    Kuerer HM, Valero V, Smith BD et al.. “Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial.” JAMA oncology (2025). PMID: 40152443 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Management Overview, Prognosis and Prognostic Factors, Special Populations
  547. [547]

    Chandarlapaty S, Chen D, He W et al.. “Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.” JAMA oncology (2016). PMID: 27532364 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation, Prognosis and Prognostic Factors
  548. [548]

    Hurvitz SA, Martin M, Press MF et al.. “Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31615937 ↗

    L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  549. [549]

    McGrady ME, Willard VW, Williams AM et al.. “Psychological Outcomes in Adolescent and Young Adult Cancer Survivors.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37967297 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  550. [550]

    Valenza C, Trapani D, Fusco N et al.. “The immunogram of inflammatory breast cancer.” Cancer treatment reviews (2023). PMID: 37437342 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
  551. [551]

    De Rose F, Meduri B, De Santis MC et al.. “Rethinking breast cancer follow-up based on individual risk and recurrence management.” Cancer treatment reviews (2022). PMID: 35933845 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  552. [552]

    Cesca MG, Vian L, Cristóvão-Ferreira S et al.. “HER2-positive advanced breast cancer treatment in 2020.” Cancer treatment reviews (2020). PMID: 32534233 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  553. [553]

    Rugo HS, Bianchini G, Cortes J et al.. “Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.” ESMO open (2022). PMID: 35964548 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  554. [554]

    Wekking D, Porcu M, Pellegrino B et al.. “Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients.” ESMO open (2023). PMID: 37951130 ↗

    L1REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
  555. [555]

    Le Rhun E, Preusser M, van den Bent M et al.. “How we treat patients with leptomeningeal metastases.” ESMO open (2019). PMID: 31231573 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  556. [556]

    Li S, Li L, Fu L. “Efficacy of different non-pharmacological therapies on cancer-related fatigue in breast cancer patients: a network meta-analysis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 42400667 ↗

    L1SR_OBSCited in: Clinical Presentation, Management Overview
  557. [557]

    Onkar SS, Carleton NM, Lucas PC et al.. “The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes.” Cancer discovery (2023). PMID: 36620880 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
  558. [558]

    Rugo HS, O'Shaughnessy J, Boyle F et al.. “Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35337972 ↗

    L1OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
  559. [559]

    Garcia-Murillas I, Abbott CW, Cutts RJ et al.. “Whole genome sequencing-powered ctDNA sequencing for breast cancer detection.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39914664 ↗

    L4OTHERCited in: Clinical Presentation
  560. [560]

    Di Meglio A, Havas J, Pagliuca M et al.. “A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39098454 ↗

    L2OTHERCited in: Clinical Presentation
  561. [561]

    Grinshpun A, Zick A, Perri T et al.. “Detection of antibody-drug conjugate-induced interstitial lung disease using circulating cell-free DNA.” ESMO open (2024). PMID: 39288654 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  562. [562]

    Parker JS, Mullins M, Cheang MC et al.. “Supervised risk predictor of breast cancer based on intrinsic subtypes.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19204204 ↗

    L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  563. [563]

    Zhang XH, Giuliano M, Trivedi MV et al.. “Metastasis dormancy in estrogen receptor-positive breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24298069 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  564. [564]

    Waning DL, Guise TA. “Molecular mechanisms of bone metastasis and associated muscle weakness.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24677373 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  565. [565]

    Body JJ. “Breast cancer: bisphosphonate therapy for metastatic bone disease.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17062710 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  566. [566]

    Li H, Wang H, Yao J et al.. “Lymphatic and Vascular Dual-System Super-Resolution Ultrasound for Diagnosing Sentinel Lymph Node Metastasis in Breast Cancer: A Prospective Study.” Ultrasound in medicine & biology (2026). PMID: 42431777 ↗

    L2COHORTCited in: Clinical Presentation
  567. [567]

    Chowdhury Q, Rahman MA, Begum FA et al.. “Breast Cancer Presentation, Treatment Patterns, and Progression-Free Survival at a Tertiary Oncology Centre in Bangladesh: A Retrospective Study.” Cancer reports (Hoboken, N.J.) (2026). PMID: 42429366 ↗

    L4COHORTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  568. [568]

    Rugo HS, Layman RM, Lynce F et al.. “Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.” ESMO open (2025). PMID: 39754979 ↗

    L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
  569. [569]

    Grinda T, Antoine A, Jacot W et al.. “Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.” ESMO open (2021). PMID: 33895695 ↗

    L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview
  570. [570]

    Tarantino P, Rugo HS, Curigliano G et al.. “Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis.” ESMO open (2025). PMID: 40516131 ↗

    L4OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
  571. [571]

    Hu H, Tong K, Tsang JY et al.. “Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.” ESMO open (2024). PMID: 38613910 ↗

    L4OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Prognosis and Prognostic Factors
  572. [572]

    Loibl S, Park YH, Shao Z et al.. “Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.” The New England journal of medicine (2025). PMID: 41370739 ↗

    L1OTHERCited in: Clinical Presentation
  573. [573]

    Fenton JJ, Taplin SH, Carney PA et al.. “Influence of computer-aided detection on performance of screening mammography.” The New England journal of medicine (2007). PMID: 17409321 ↗

    L2OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis
  574. [574]

    Garcia-Murillas I, Chopra N, Comino-Méndez I et al.. “Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.” JAMA oncology (2019). PMID: 31369045 ↗

    L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Special Populations
  575. [575]

    Caan BJ, Cespedes Feliciano EM, Prado CM et al.. “Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.” JAMA oncology (2018). PMID: 29621380 ↗

    L2OTHERCited in: Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors
  576. [576]

    Taylor BC, Sun X, Gonzalez-Ericsson PI et al.. “NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer.” Cancer discovery (2024). PMID: 37791898 ↗

    L5OTHERCited in: Clinical Presentation
  577. [577]

    Tarantino P, Curigliano G, Tolaney SM. “Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons.” Cancer discovery (2022). PMID: 35856622 ↗

    L5OTHERCited in: Clinical Presentation, History and Evolution of Treatment
  578. [578]

    Wang D, DuBois RN. “The role of the PGE2-aromatase pathway in obesity-associated breast inflammation.” Cancer discovery (2012). PMID: 22576207 ↗

    L5OTHERCited in: Clinical Presentation
  579. [579]

    Foidart P, Li Z, Cai X et al.. “Whole-genome doubling drives immune evasion by silencing antigen presentation.” Cancer cell (2026). PMID: 42102810 ↗

    L5OTHERCited in: Clinical Presentation, History and Evolution of Treatment
  580. [580]

    Engelhardt JJ, Boldajipour B, Beemiller P et al.. “Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells.” Cancer cell (2012). PMID: 22439936 ↗

    L5OTHERCited in: Clinical Presentation
  581. [581]

    Dravis C, Chung CY, Lytle NK et al.. “Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity.” Cancer cell (2018). PMID: 30174241 ↗

    L5OTHERCited in: Clinical Presentation
  582. [582]

    Kim HS, Kim HJ. “Effectiveness of a Smartphone-Based Self-Management App (BeHealth app) for Women with Breast Cancer: A Randomized Controlled Trial.” Iranian journal of public health (2025). PMID: 42428742 ↗

    L1RCTCited in: Clinical Presentation
  583. [583]

    Bistriceanu I, Stoica RA, Iordache N et al.. “Clinicopathological and immunohistochemical profile of breast lesions diagnosed by core needle biopsy: a retrospective study from Sf. Ioan Hospital, Bucharest, Romania.” Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie (2026). PMID: 42402738 ↗

    L4COHORTCited in: Clinical Presentation, Biopsy and Histologic Diagnosis
  584. [584]

    Abdalaty S, Chai GW, Sferrazza D et al.. “The impact of maternal breast cancer diagnosis on the mother-child relationship: an updated systematic review.” Current opinion in supportive and palliative care (2026). PMID: 42417076 ↗

    L5SR_OBSCited in: Clinical Presentation
  585. [585]

    Rakha EA. “Flat epithelial atypia of the breast: a pragmatic, context-integrated diagnostic framework within a biological continuum.” Histopathology (2026). PMID: 42411107 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  586. [586]

    Dent R, Trudeau M, Pritchard KI et al.. “Triple-negative breast cancer: clinical features and patterns of recurrence.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17671126 ↗

    L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  587. [587]

    Gitto SB, Whicker M, Davies G et al.. “A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 37882675 ↗

    L5OTHERCited in: Clinical Presentation
  588. [588]

    Freedman RA, Partridge AH. “Emerging Data and Current Challenges for Young, Old, Obese, or Male Patients with Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28572259 ↗

    L5OTHERCited in: Clinical Presentation
  589. [589]

    Rennert G, Pinchev M, Gronich N et al.. “Oral Bisphosphonates and Improved Survival of Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27683176 ↗

    L3OTHERCited in: Clinical Presentation, Staging
  590. [590]

    Gradishar WJ, Anderson BO, Balassanian R et al.. “NCCN Guidelines Insights: Breast Cancer, Version 1.2017.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28404755 ↗

    L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Imaging, Staging, Prognosis and Prognostic Factors
  591. [591]

    Abulkhair O, Saghir N, Sedky L et al.. “Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20697133 ↗

    L5GUIDELINECited in: Biopsy and Histologic Diagnosis
  592. [592]

    Conte PF, Dieci MV, Bisagni G et al.. “A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40885530 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis
  593. [593]

    Park KU, Somerfield MR, Anne N et al.. “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40209128 ↗

    L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Staging, History and Evolution of Treatment
  594. [594]

    Allison KH, Hammond MEH, Dowsett M et al.. “Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 31928404 ↗

    L1GUIDELINECited in: Biopsy and Histologic Diagnosis, History and Evolution of Treatment
  595. [595]

    Wolff AC, Somerfield MR, Dowsett M et al.. “Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37284804 ↗

    L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  596. [596]

    Wolff AC, Hammond MEH, Allison KH et al.. “Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29846122 ↗

    L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  597. [597]

    Andre F, Ismaila N, Allison KH et al.. “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35439025 ↗

    L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Management Overview
  598. [598]

    Wolff AC, Hammond ME, Hicks DG et al.. “Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24101045 ↗

    L1GUIDELINECited in: Biopsy and Histologic Diagnosis
  599. [599]

    Garrigós L, Ruiz-Borrego M, Pérez-García JM et al.. “A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 42097893 ↗

    L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  600. [600]

    Modi S, Park H, Murthy RK et al.. “Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32058843 ↗

    L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  601. [601]

    Bardia A, Mayer IA, Diamond JR et al.. “Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28291390 ↗

    L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  602. [602]

    Hu X, Curigliano G, Yonemori K et al.. “Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial.” ESMO open (2025). PMID: 40441802 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Special Populations
  603. [603]

    Donker M, van Tienhoven G, Straver ME et al.. “Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.” The Lancet. Oncology (2014). PMID: 25439688 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  604. [604]

    Galimberti V, Cole BF, Zurrida S et al.. “Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.” The Lancet. Oncology (2013). PMID: 23491275 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis
  605. [605]

    Bonnefoi H, Lerebours F, Pulido M et al.. “Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.” The Lancet. Oncology (2025). PMID: 39978376 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis
  606. [606]

    Yuan J, Bi XW, Hua X et al.. “Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial.” The Lancet. Oncology (2025). PMID: 41308674 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis
  607. [607]

    Mamounas EP, Bandos H, White JR et al.. “Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.” The New England journal of medicine (2025). PMID: 40466065 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  608. [608]

    Weaver DL, Ashikaga T, Krag DN et al.. “Effect of occult metastases on survival in node-negative breast cancer.” The New England journal of medicine (2011). PMID: 21247310 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis
  609. [609]

    Piha-Paul SA, Tseng C, Tran HT et al.. “Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations.” ESMO open (2025). PMID: 39908697 ↗

    L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  610. [610]

    Denkert C, Seither F, Schneeweiss A et al.. “Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.” The Lancet. Oncology (2021). PMID: 34252375 ↗

    L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  611. [611]

    Kuemmel S, Graeser M, Schmid P et al.. “Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.” The Lancet. Oncology (2025). PMID: 40318646 ↗

    L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  612. [612]

    Dilawari A, Zhang H, Shah M et al.. “US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40763319 ↗

    L5RCTCited in: Biopsy and Histologic Diagnosis
  613. [613]

    Mariotti V, Han H, Ismail-Khan R et al.. “Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33151286 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis
  614. [614]

    Weber WP, Davide Gentilini O, Morrow M et al.. “Uncertainties and controversies in axillary management of patients with breast cancer.” Cancer treatment reviews (2023). PMID: 37126938 ↗

    L5SR_OBSCited in: Biopsy and Histologic Diagnosis
  615. [615]

    Verschoor N, Deger T, Jager A et al.. “Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review.” Cancer treatment reviews (2022). PMID: 35366566 ↗

    L5SR_OBSCited in: Biopsy and Histologic Diagnosis
  616. [616]

    Yucel KB, Ilhan Y, Almuradova E et al.. “Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis.” Cancer treatment reviews (2026). PMID: 41512603 ↗

    L1SR_OBSCited in: Biopsy and Histologic Diagnosis
  617. [617]

    Ahmed M, Purushotham AD, Douek M. “Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review.” The Lancet. Oncology (2014). PMID: 24988938 ↗

    L2SR_OBSCited in: Biopsy and Histologic Diagnosis
  618. [618]

    Lehman CD, DeMartini W, Anderson BO et al.. “Indications for breast MRI in the patient with newly diagnosed breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19200417 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Imaging, Staging, Prognosis and Prognostic Factors
  619. [619]

    Anderson BO, Calhoun KE, Rosen EL. “Evolving concepts in the management of lobular neoplasia.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16687097 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  620. [620]

    Allred DC, Carlson RW, Berry DA et al.. “NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19755043 ↗

    L1REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  621. [621]

    Whelan TJ, Olivotto IA, Parulekar WR et al.. “Regional Nodal Irradiation in Early-Stage Breast Cancer.” The New England journal of medicine (2015). PMID: 26200977 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis, Staging
  622. [622]

    Poortmans PM, Collette S, Kirkove C et al.. “Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.” The New England journal of medicine (2015). PMID: 26200978 ↗

    L1RCTCited in: Biopsy and Histologic Diagnosis
  623. [623]

    Wander SA, Cohen O, Gong X et al.. “The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.” Cancer discovery (2020). PMID: 32404308 ↗

    L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  624. [624]

    Visvanathan K, Cope L, Fackler MJ et al.. “Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36534524 ↗

    L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  625. [625]

    Tsuji J, Li T, Grinshpun A et al.. “Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 36215125 ↗

    L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
  626. [626]

    Wotman MT, Khalaf A, Wang K et al.. “Trastuzumab Deruxtecan in HER2-Low or HER2-Mutant Recurrent/Metastatic Secretory Gland Cancers of the Head and Neck: A Case Series.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41213241 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
  627. [627]

    Penault-Llorca F, Viale G. “Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23012297 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  628. [628]

    Aapro M, Wildiers H. “Triple-negative breast cancer in the older population.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23012304 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  629. [629]

    Oliveira M, Cortés J, Bellet M et al.. “Management of the axilla in early breast cancer patients in the genomic era.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23165977 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Imaging
  630. [630]

    Viale G, Basik M, Niikura N et al.. “Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.” ESMO open (2023). PMID: 37562195 ↗

    L4COHORTCited in: Biopsy and Histologic Diagnosis
  631. [631]

    Kuehn T, Bauerfeind I, Fehm T et al.. “Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.” The Lancet. Oncology (2013). PMID: 23683750 ↗

    L2COHORTCited in: Biopsy and Histologic Diagnosis, Staging, Special Populations
  632. [632]

    Montagna G, Alvarado M, Myers S et al.. “Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study.” The Lancet. Oncology (2026). PMID: 41449148 ↗

    L3COHORTCited in: Biopsy and Histologic Diagnosis
  633. [633]

    Ly A, Ono JC, Hughes KS et al.. “Fine-Needle Aspiration Biopsy of Palpable Breast Masses: Patterns of Clinical Use and Patient Experience.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27160231 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  634. [634]

    Kamal AH, Power S, Broadwater G et al.. “Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24614047 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  635. [635]

    Hamilton E, Shastry M, Shiller SM et al.. “Targeting HER2 heterogeneity in breast cancer.” Cancer treatment reviews (2021). PMID: 34534820 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  636. [636]

    Harbeck N, Salem M, Nitz U et al.. “Personalized treatment of early-stage breast cancer: present concepts and future directions.” Cancer treatment reviews (2010). PMID: 20554119 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Staging, Special Populations
  637. [637]

    Buono G, Gerratana L, Bulfoni M et al.. “Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?” Cancer treatment reviews (2019). PMID: 30682661 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  638. [638]

    Lin X, Liu B, Wu J et al.. “Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation.” Cancer treatment reviews (2026). PMID: 41702297 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  639. [639]

    Perez EA, Cortés J, Gonzalez-Angulo AM et al.. “HER2 testing: current status and future directions.” Cancer treatment reviews (2013). PMID: 24080154 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  640. [640]

    van de Ven S, Smit VT, Dekker TJ et al.. “Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.” Cancer treatment reviews (2010). PMID: 21177040 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  641. [641]

    Muñoz M, Estévez LG, Alvarez I et al.. “Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.” Cancer treatment reviews (2008). PMID: 18922644 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Staging
  642. [642]

    Senkus E, Cardoso MJ, Kaidar-Person O et al.. “De-escalation of axillary irradiation for early breast cancer - Has the time come?” Cancer treatment reviews (2021). PMID: 34656018 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  643. [643]

    Shimozaki K, Fukuoka S, Ooki A et al.. “HER2-low gastric cancer: is the subgroup targetable?” ESMO open (2024). PMID: 39178538 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview
  644. [644]

    Curigliano G, Dent R, Earle H et al.. “Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.” ESMO open (2024). PMID: 38613914 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  645. [645]

    Henskens IJ, Dinger TL, Stekelenburg I et al.. “Fluorescence imaging using indocyanine green to identify sentinel lymph nodes during surgery for breast cancer (INFINITE): protocol for a hybrid effectiveness-implementation trial using a stepped-wedge cluster design.” BMJ open (2026). PMID: 42342397 ↗

    L5TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis, Imaging
  646. [646]

    Wael N, Owid AZ, Fadlalla H. “Diagnostic performance of circulating cell-free DNA as a minimally invasive biomarker for breast cancer: a systematic review and meta-analysis of methylation, quantitative, and integrity markers.” Expert review of molecular diagnostics (2026). PMID: 42266071 ↗

    L1SR_OBSCited in: Biopsy and Histologic Diagnosis
  647. [647]

    Pilewskie M, Morrow M. “Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review.” JAMA oncology (2017). PMID: 27918753 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  648. [648]

    Uzunparmak B, Haymaker C, Raso G et al.. “HER2-low expression in patients with advanced or metastatic solid tumors.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37619847 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  649. [649]

    Szekely B, Bossuyt V, Li X et al.. “Immunological differences between primary and metastatic breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 30203045 ↗

    L3OTHERCited in: Biopsy and Histologic Diagnosis
  650. [650]

    Curigliano G, Viale G, Ghioni M et al.. “Cancer-testis antigen expression in triple-negative breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20610479 ↗

    L3OTHERCited in: Biopsy and Histologic Diagnosis, Staging
  651. [651]

    Schmid P, Wang HC, Lynce F et al.. “Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 42167437 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  652. [652]

    Choong GM, Hoskin TL, Boughey JC et al.. “Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40215443 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Staging, Management Overview
  653. [653]

    Nishikawa T, Hasegawa K, Matsumoto K et al.. “Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36977309 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  654. [654]

    Andre F, Dieci MV, Dubsky P et al.. “Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 23258741 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  655. [655]

    Yaal-Hahoshen N, Shina S, Leider-Trejo L et al.. “The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16899591 ↗

    L2REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  656. [656]

    Walbaum B, Martínez-Sáez O, Brasó-Maristany F et al.. “Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer.” ESMO open (2025). PMID: 40997745 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  657. [657]

    Pesántez D, Brasó-Maristany F, Pascual T et al.. “HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy.” ESMO open (2025). PMID: 40913834 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  658. [658]

    Wu S, Shang J, Li Z et al.. “Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter study.” ESMO open (2025). PMID: 39891991 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  659. [659]

    Reimer T, Stachs A, Veselinovic K et al.. “Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.” The New England journal of medicine (2024). PMID: 39665649 ↗

    L1OTHERCited in: Biopsy and Histologic Diagnosis, Imaging, Staging, Management Overview, Prognosis and Prognostic Factors
  660. [660]

    de Boniface J, Filtenborg Tvedskov T, Rydén L et al.. “Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.” The New England journal of medicine (2024). PMID: 38598571 ↗

    L1OTHERCited in: Biopsy and Histologic Diagnosis
  661. [661]

    de Boer M, van Deurzen CH, van Dijck JA et al.. “Micrometastases or isolated tumor cells and the outcome of breast cancer.” The New England journal of medicine (2009). PMID: 19675329 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis, Staging
  662. [662]

    Fernandez AI, Liu M, Bellizzi A et al.. “Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.” JAMA oncology (2022). PMID: 35113160 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
  663. [663]

    Montagna G, Zhang J, Sevilimedu V et al.. “Risk Factors and Racial and Ethnic Disparities in Patients With Breast Cancer-Related Lymphedema.” JAMA oncology (2022). PMID: 35679026 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  664. [664]

    Menes TS, Kerlikowske K, Lange J et al.. “Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy.” JAMA oncology (2017). PMID: 27607465 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  665. [665]

    Waks AG, Ogayo ER, Paré L et al.. “Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.” JAMA oncology (2023). PMID: 37103927 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  666. [666]

    Prat A, Bardia A, Curigliano G et al.. “An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low).” JAMA oncology (2022). PMID: 36107417 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis
  667. [667]

    Barrio AV, Montagna G, Mamtani A et al.. “Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.” JAMA oncology (2021). PMID: 34617979 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  668. [668]

    Cunningham N, Turner NC. “Liquid Biopsies in Breast Milk for the Early Detection of Breast Cancer.” Cancer discovery (2023). PMID: 37794840 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis
  669. [669]

    . “Rapid Diagnostic May Improve Breast Cancer Care.” Cancer discovery (2020). PMID: 32988962 ↗

    L5OTHERCited in: Biopsy and Histologic Diagnosis
  670. [670]

    Strand SH, Rivero-Gutiérrez B, Houlahan KE et al.. “Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.” Cancer cell (2022). PMID: 36400020 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  671. [671]

    Liang Y, Wu K, Pan L et al.. “Tertiary lymphoid structures in breast cancer: Mechanistic insights, subtype-specific patterns, and therapeutic implications.” World journal of surgical oncology (2026). PMID: 42351178 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  672. [672]

    Pekarek L, García-Montero C, Casanova-Martin C et al.. “Beyond Molecular Classification in Metastatic Triple-Negative Breast Cancer: Toward Subtype-Guided Precision Oncology.” International journal of molecular sciences (2026). PMID: 42278564 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  673. [673]

    Scurtu AG, Sala DT, Jung I et al.. “HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies.” International journal of molecular sciences (2026). PMID: 42278208 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  674. [674]

    Kroemer M, Lopez M, Mansi L et al.. “Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.” Expert opinion on investigational drugs (2026). PMID: 42258224 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  675. [675]

    Balakrishnan A, Goodpaster T, Randolph-Habecker J et al.. “Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27852699 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  676. [676]

    Gouda MA, Gonugunta A, Dumbrava EE et al.. “Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39841861 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis, Management Overview, Prognosis and Prognostic Factors
  677. [677]

    Dolled-Filhart M, Rydén L, Cregger M et al.. “Classification of breast cancer using genetic algorithms and tissue microarrays.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17085660 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  678. [678]

    Piscuoglio S, Ng CK, Murray MP et al.. “The Genomic Landscape of Male Breast Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26960396 ↗

    L4OTHERCited in: Biopsy and Histologic Diagnosis
  679. [679]

    Downs BM, Mercado-Rodriguez C, Cimino-Mathews A et al.. “DNA Methylation Markers for Breast Cancer Detection in the Developing World.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31300453 ↗

    L3OTHERCited in: Biopsy and Histologic Diagnosis
  680. [680]

    Badve S, Turbin D, Thorat MA et al.. “FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17671124 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  681. [681]

    Jhaveri K, Rugo HS, Cortés J et al.. “Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 42154572 ↗

    L2OTHERCited in: Biopsy and Histologic Diagnosis
  682. [682]

    Stratton M, Davies J, Joshi H. “Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis-generating perspective.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 42396616 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  683. [683]

    Dolu F, Ay OF, Akgün IE et al.. “Predictors of sentinel lymph node metastasis in cT1-2 cN0 breast cancer: A retrospective cohort study.” Medicine (2026). PMID: 42410794 ↗

    L2COHORTCited in: Biopsy and Histologic Diagnosis, Imaging, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  684. [684]

    Surendran HP, Dutta D, Unnikrishnan MK et al.. “Concordance of Receptor Expression Status in the Primary Breast Tumor and in Breast Cancer Metastasized into the Brain: Analysis from an Indian Cohort Prospective Study (CTRI/2022/01/039599).” Indian journal of surgical oncology (2025). PMID: 42381785 ↗

    L2COHORTCited in: Biopsy and Histologic Diagnosis
  685. [685]

    Perry N, Broeders M, de Wolf C et al.. “European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 18024988 ↗

    L1GUIDELINECited in: Imaging
  686. [686]

    Im SA, Gennari A, Park YH et al.. “Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer.” ESMO open (2023). PMID: 37178669 ↗

    L1GUIDELINECited in: Imaging
  687. [687]

    Mulder RL, Kremer LC, Hudson MM et al.. “Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.” The Lancet. Oncology (2013). PMID: 24275135 ↗

    L1GUIDELINECited in: Imaging
  688. [688]

    Houssami N, Costelloe CM. “Imaging bone metastases in breast cancer: evidence on comparative test accuracy.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21896542 ↗

    L1SR_OBSCited in: Imaging
  689. [689]

    Turner NC, Swift C, Jenkins B et al.. “Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 36423745 ↗

    L2RCTCited in: Imaging
  690. [690]

    Houssami N, Turner R, Macaskill P et al.. “An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24395846 ↗

    L1SR_OBSCited in: Imaging
  691. [691]

    van Geel JJL, Boers J, Elias SG et al.. “Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35584346 ↗

    L2SR_OBSCited in: Imaging
  692. [692]

    Woodward WA, Vinh-Hung V, Ueno NT et al.. “Prognostic value of nodal ratios in node-positive breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16782931 ↗

    L2SR_OBSCited in: Imaging
  693. [693]

    Loibl S, Marmé F, Martin M et al.. “Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33793299 ↗

    L1RCTCited in: Imaging
  694. [694]

    García-Mosquera JJ, Pérez-García JM, Ruiz-Borrego M et al.. “Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial.” ESMO open (2025). PMID: 41202503 ↗

    L2RCTCited in: Imaging
  695. [695]

    Hatschek T, Foukakis T, Bjöhle J et al.. “Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.” JAMA oncology (2021). PMID: 34165503 ↗

    L1RCTCited in: Imaging
  696. [696]

    Pabst KM, Weber MM, Laschinsky C et al.. “[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial.” The Lancet. Oncology (2025). PMID: 40774265 ↗

    L4TRIAL_NONRANDOMCited in: Imaging
  697. [697]

    van der Voort A, Louis FM, van Ramshorst MS et al.. “MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.” The Lancet. Oncology (2024). PMID: 38588682 ↗

    L4TRIAL_NONRANDOMCited in: Imaging
  698. [698]

    Bénard F, Harsini S, Wilson D et al.. “Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.” The Lancet. Oncology (2022). PMID: 36343655 ↗

    L2TRIAL_NONRANDOMCited in: Imaging
  699. [699]

    Shih J, Bashir B, Gustafson KS et al.. “Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26285240 ↗

    L4CASE_REPORTCited in: Imaging
  700. [700]

    McDonald ES, Doot RK, Pantel AR et al.. “Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial.” JAMA oncology (2020). PMID: 32297911 ↗

    L4TRIAL_NONRANDOMCited in: Imaging
  701. [701]

    Kjeldsted E, Ammitzbøll G, Lænkholm AV et al.. “Effects of Supervised Exercise during Neoadjuvant Chemotherapy on Tumor Response in Patients with Breast Cancer (Neo-train): A Randomized Controlled Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40788186 ↗

    L1RCTCited in: Imaging, Management Overview, History and Evolution of Treatment
  702. [702]

    Formenti SC, Lee P, Adams S et al.. “Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29476019 ↗

    L1RCTCited in: Imaging
  703. [703]

    Carlson RW, Moench S, Hurria A et al.. “NCCN Task Force Report: breast cancer in the older woman.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18597715 ↗

    L1REVIEW_NARRATIVECited in: Imaging
  704. [704]

    Le-Petross HT. “Breast MRI as a screening tool: the appropriate role.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16687098 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  705. [705]

    Ko H, Baghdadi Y, Love C et al.. “Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32886897 ↗

    L2OTHERCited in: Imaging
  706. [706]

    Edge SB. “Advances in breast surgery, 2002-2012.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23307981 ↗

    L5OTHERCited in: Imaging
  707. [707]

    Kamal A, Zhang T, Power S et al.. “Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27496115 ↗

    L2OTHERCited in: Imaging
  708. [708]

    Di Meglio A, Lin NU, Freedman RA et al.. “Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28275032 ↗

    L2OTHERCited in: Imaging
  709. [709]

    Hyland CJ, Varghese F, Yau C et al.. “Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 33152704 ↗

    L2OTHERCited in: Imaging
  710. [710]

    Sahin AA, Gilligan TD, Caudell JJ. “Challenges With the 8th Edition of the AJCC Cancer Staging Manual for Breast, Testicular, and Head and Neck Cancers.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31117030 ↗

    L5OTHERCited in: Imaging
  711. [711]

    Podoloff DA, Advani RH, Allred C et al.. “NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2007). PMID: 17509259 ↗

    L1OTHERCited in: Imaging
  712. [712]

    Starodub AN, Ocean AJ, Shah MA et al.. “First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25944802 ↗

    L4TRIAL_NONRANDOMCited in: Imaging, Management Overview
  713. [713]

    Kenny LM, Contractor KB, Hinz R et al.. “Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20682702 ↗

    L4TRIAL_NONRANDOMCited in: Imaging
  714. [714]

    Martín M, Stecklein SR, Gluz O et al.. “TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39419289 ↗

    L2OTHERCited in: Imaging, Staging
  715. [715]

    Woolf DK, Padhani AR, Makris A. “Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25471332 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  716. [716]

    Lynch SP, Lei X, Chavez-MacGregor M et al.. “Multifocality and multicentricity in breast cancer and survival outcomes.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22776706 ↗

    L2OTHERCited in: Imaging
  717. [717]

    Cinieri S, Orlando L, Fedele P et al.. “Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591835 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  718. [718]

    Pike MC, Pearce CL. “Mammographic density, MRI background parenchymal enhancement and breast cancer risk.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24131968 ↗

    L5OTHERCited in: Imaging
  719. [719]

    Sanna G, Preda L, Bruschini R et al.. “Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16936182 ↗

    L2OTHERCited in: Imaging
  720. [720]

    Wishart GC, Greenberg DC, Chou P et al.. “Treatment and survival in breast cancer in the Eastern Region of England.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19502647 ↗

    L2OTHERCited in: Imaging
  721. [721]

    Bernsdorf M, Berthelsen AK, Wielenga VT et al.. “Preoperative PET/CT in early-stage breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22357250 ↗

    L2OTHERCited in: Imaging
  722. [722]

    Winchester DJ, Singh L, Edge SB et al.. “Novel Postneoadjuvant Prognostic Breast Cancer Staging System.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40215445 ↗

    L2OTHERCited in: Imaging, Staging
  723. [723]

    Orel S. “Who should have breast magnetic resonance imaging evaluation?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18258977 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  724. [724]

    Hodgson NC, Gulenchyn KY. “Is there a role for positron emission tomography in breast cancer staging?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18258978 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  725. [725]

    Zakhireh J, Fowble B, Esserman LJ. “Application of screening principles to the reconstructed breast.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19884555 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  726. [726]

    Cooke R, Baxter P, Wyld L et al.. “Factors influencing women's preferences and decision making regarding the extent of axillary surgery in breast cancer: A systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42330708 ↗

    L2SR_OBSCited in: Imaging
  727. [727]

    Bartram A, Gilbert F, Thompson A et al.. “Breast MRI in DCIS size estimation, breast-conserving surgery and oncoplastic breast surgery.” Cancer treatment reviews (2021). PMID: 33610127 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  728. [728]

    Miglietta F, Fabi A, Generali D et al.. “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review.” Cancer treatment reviews (2023). PMID: 36638600 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  729. [729]

    Pantaleo MA, Nannini M, Maleddu A et al.. “Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy.” Cancer treatment reviews (2007). PMID: 18055120 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  730. [730]

    Persano I, Licata L, Piras M et al.. “De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice.” Cancer treatment reviews (2026). PMID: 41570550 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  731. [731]

    Ponzone R, Ruatta F, Gatti M et al.. “Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer.” Cancer treatment reviews (2016). PMID: 27262016 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  732. [732]

    Valle I, Ribeiro JM, Grinda T et al.. “Progress toward personalized management of stage II/III triple negative breast cancer.” Cancer treatment reviews (2026). PMID: 42068737 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  733. [733]

    Li Z, Kang D, Xu S et al.. “Collagen signature adds prognostically significant information to staging for breast cancer.” ESMO open (2024). PMID: 39577107 ↗

    L2OTHERCited in: Imaging, Staging
  734. [734]

    Wu S, Hong G, Xu A et al.. “Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study.” The Lancet. Oncology (2023). PMID: 36893772 ↗

    L2OTHERCited in: Imaging
  735. [735]

    Fowler AM, Strigel RM. “Clinical advances in PET-MRI for breast cancer.” The Lancet. Oncology (2022). PMID: 34973230 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  736. [736]

    Fouad TM, Barrera AMG, Reuben JM et al.. “Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.” The Lancet. Oncology (2017). PMID: 28368261 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  737. [737]

    Costelloe CM, Rohren EM, Madewell JE et al.. “Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis.” The Lancet. Oncology (2009). PMID: 19482249 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  738. [738]

    Jatoi I, Benson JR, Toi M. “De-escalation of axillary surgery in early breast cancer.” The Lancet. Oncology (2016). PMID: 27733269 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  739. [739]

    van Kruchten M, de Vries EGE, Brown M et al.. “PET imaging of oestrogen receptors in patients with breast cancer.” The Lancet. Oncology (2013). PMID: 24079874 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  740. [740]

    Anderson BO, Cazap E, El Saghir NS et al.. “Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010.” The Lancet. Oncology (2011). PMID: 21463833 ↗

    L1OTHERCited in: Imaging
  741. [741]

    Pfob A, Pham TH, de Boniface J et al.. “Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials.” The Lancet. Oncology (2026). PMID: 42061372 ↗

    L1OTHERCited in: Imaging
  742. [742]

    Tomala J, Upadhyay N. “Comparative Analysis of CEM and Breast MRI: A Retrospective Study.” Journal of surgical oncology (2026). PMID: 42394378 ↗

    L3COHORTCited in: Imaging
  743. [743]

    van Hemert AKE, van Loevezijn AA, Baas MPD et al.. “Iodine Seed-Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast Cancer.” JAMA oncology (2025). PMID: 40875213 ↗

    L2OTHERCited in: Imaging
  744. [744]

    Geuzinge HA, Obdeijn IM, Rutgers EJT et al.. “Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.” JAMA oncology (2020). PMID: 32729887 ↗

    L2OTHERCited in: Imaging
  745. [745]

    Arnaout A, Catley C, Booth CM et al.. “Use of Preoperative Magnetic Resonance Imaging for Breast Cancer: A Canadian Population-Based Study.” JAMA oncology (2015). PMID: 26402040 ↗

    L2OTHERCited in: Imaging
  746. [746]

    Cho N, Han W, Han BK et al.. “Breast Cancer Screening With Mammography Plus Ultrasonography or Magnetic Resonance Imaging in Women 50 Years or Younger at Diagnosis and Treated With Breast Conservation Therapy.” JAMA oncology (2017). PMID: 28655029 ↗

    L2OTHERCited in: Imaging
  747. [747]

    Mittendorf EA, Vila J, Tucker SL et al.. “The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.” JAMA oncology (2016). PMID: 26986538 ↗

    L2OTHERCited in: Imaging
  748. [748]

    Weiss A, Chavez-MacGregor M, Lichtensztajn DY et al.. “Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.” JAMA oncology (2018). PMID: 29222540 ↗

    L2OTHERCited in: Imaging
  749. [749]

    Patnaik A, Rosen LS, Tolaney SM et al.. “Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.” Cancer discovery (2016). PMID: 27217383 ↗

    L4OTHERCited in: Imaging, Staging, Prognosis and Prognostic Factors
  750. [750]

    Junankar S, Shay G, Jurczyluk J et al.. “Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer.” Cancer discovery (2014). PMID: 25312016 ↗

    L5OTHERCited in: Imaging
  751. [751]

    van Kruchten M, de Vries EG, Glaudemans AW et al.. “Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.” Cancer discovery (2014). PMID: 25380844 ↗

    L4OTHERCited in: Imaging
  752. [752]

    Ros S, Wright AJ, D'Santos P et al.. “Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer.” Cancer cell (2020). PMID: 32976773 ↗

    L5OTHERCited in: Imaging
  753. [753]

    Yang Y, Lin T, Li J et al.. “Clinical and Imaging Characteristics in the Diagnosis and Surgical Management of Nipple Discharge Without Clinically Palpable Masses: A Retrospective Cohort Study.” Thoracic cancer (2026). PMID: 42338287 ↗

    L3COHORTCited in: Imaging
  754. [754]

    Mao J, Song J, Liu Y et al.. “Dynamic contrast-enhanced magnetic resonance imaging-derived three-dimensional tumor volume improves prognostic stratification in breast cancer: a retrospective cohort study.” Gland surgery (2026). PMID: 42299284 ↗

    L3COHORTCited in: Imaging, Staging
  755. [755]

    Linden HM, Mankoff DA. “Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36988617 ↗

    L5OTHERCited in: Imaging
  756. [756]

    Diot G, Metz S, Noske A et al.. “Multispectral Optoacoustic Tomography (MSOT) of Human Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28899968 ↗

    L4OTHERCited in: Imaging
  757. [757]

    Iqbal R, Yaqub M, Bektas HO et al.. “[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36735488 ↗

    L4OTHERCited in: Imaging
  758. [758]

    Gough M, Kwah KKX, Khan T et al.. “Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39869307 ↗

    L4OTHERCited in: Imaging
  759. [759]

    Cheng VWT, de Pennington N, Zakaria R et al.. “VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35312755 ↗

    L5OTHERCited in: Imaging
  760. [760]

    Andreassen MMS, Rodríguez-Soto AE, Conlin CC et al.. “Discrimination of Breast Cancer from Healthy Breast Tissue Using a Three-component Diffusion-weighted MRI Model.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 33148675 ↗

    L2OTHERCited in: Imaging
  761. [761]

    Nie P, Kalidindi T, Nagle VL et al.. “Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34475100 ↗

    L5OTHERCited in: Imaging
  762. [762]

    Mishra A, Kumar D, Gupta K et al.. “Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36449662 ↗

    L5OTHERCited in: Imaging
  763. [763]

    Contractor KB, Kenny LM, Stebbing J et al.. “[11C]choline positron emission tomography in estrogen receptor-positive breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19706823 ↗

    L4OTHERCited in: Imaging
  764. [764]

    Yang W, Li H, Shen D et al.. “Report of a case of renal hilum Castleman disease complicated with Paget's disease of the breast.” Frontiers in medicine (2026). PMID: 42318394 ↗

    L4CASE_REPORTCited in: Imaging
  765. [765]

    Taleb I, Witmeyer S, Huck C et al.. “Adenoid cystic carcinoma of the breast: a case series of 26 patients.” Breast cancer research and treatment (2026). PMID: 42283891 ↗

    L4CASE_REPORTCited in: Imaging
  766. [766]

    Toyota PR, Hounjet CD, Liu E et al.. “Tumor-to-Tumor Metastasis Involving Vestibular Schwannoma: Case Report and Literature Review.” Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology (2026). PMID: 42283164 ↗

    L4CASE_REPORTCited in: Imaging
  767. [767]

    Zhang L, Birla S, Tang SX et al.. “Impact of Total and Positive Lymph Node Count on Recurrence in Young Women with Node-Positive Breast Cancer Undergoing Neoadjuvant Chemotherapy.” Annals of surgical oncology (2026). PMID: 42420636 ↗

    L3OTHERCited in: Imaging
  768. [768]

    Venkatesh H, Castro Gierach G, Kanzaki L et al.. “Pregnancy-Associated Breast Cancer: A Trimester and Subtype Based Clinical Decision Framework for the Surgeon and Surgical Trainee.” Annals of surgical oncology (2026). PMID: 42390665 ↗

    L5REVIEW_NARRATIVECited in: Imaging
  769. [769]

    Giordano SH, Elias AD, Gradishar WJ. “NCCN Guidelines Updates: Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29784737 ↗

    L1GUIDELINECited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  770. [770]

    Yang SX, Yu J, Wang M. “21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39019060 ↗

    L2RCTCited in: Molecular Diagnostics and Biomarkers
  771. [771]

    Wu W, Yang Y, Yang W et al.. “Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative Breast Cancer in the CBCSG010 Clinical Trial Biomarker Analysis.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39413834 ↗

    L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
  772. [772]

    Hortobagyi GN, Lacko A, Sohn J et al.. “A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39442617 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  773. [773]

    Harbeck N, Modi S, Pusztai L et al.. “Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41130363 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Special Populations
  774. [774]

    Goetz MP, Toi M, Huober J et al.. “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38729566 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  775. [775]

    Schneeweiss A, Chia S, Hickish T et al.. “Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23704196 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment
  776. [776]

    Hortobagyi GN, Stemmer SM, Burris HA et al.. “Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29718092 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Special Populations
  777. [777]

    Johnston S, Martin M, O'Shaughnessy J et al.. “Overall survival with abemaciclib in early breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41110697 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  778. [778]

    Harbeck N, Rastogi P, Martin M et al.. “Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34656740 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  779. [779]

    Johnston SRD, Harbeck N, Hegg R et al.. “Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32954927 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  780. [780]

    Bidard FC, Kaklamani VG, Neven P et al.. “Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35584336 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  781. [781]

    Goetz MP, Toi M, Campone M et al.. “MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28968163 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Special Populations
  782. [782]

    Bardia A, Jhaveri K, Im SA et al.. “Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39265124 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  783. [783]

    Sledge GW, Toi M, Neven P et al.. “MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28580882 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  784. [784]

    Bardia A, Rugo HS, Tolaney SM et al.. “Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38422473 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  785. [785]

    Slamon DJ, Neven P, Chia S et al.. “Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29860922 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  786. [786]

    Saura C, Modi S, Krop I et al.. “Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 38092229 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  787. [787]

    Bardia A, Krop IE, Kogawa T et al.. “Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38652877 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  788. [788]

    Crown J, Stroyakovskii D, Yardley DA et al.. “Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.” ESMO open (2025). PMID: 41320342 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  789. [789]

    Hurvitz SA, Kim SB, Chung WP et al.. “Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.” ESMO open (2024). PMID: 38796287 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  790. [790]

    Swain SM, Miles D, Kim SB et al.. “Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.” The Lancet. Oncology (2020). PMID: 32171426 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  791. [791]

    Bidard FC, Hardy-Bessard AC, Dalenc F et al.. “Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.” The Lancet. Oncology (2022). PMID: 36183733 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  792. [792]

    van Ramshorst MS, van der Voort A, van Werkhoven ED et al.. “Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2018). PMID: 30413379 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  793. [793]

    Gianni L, Pienkowski T, Im YH et al.. “Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.” The Lancet. Oncology (2011). PMID: 22153890 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  794. [794]

    Gianni L, Pienkowski T, Im YH et al.. “5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.” The Lancet. Oncology (2016). PMID: 27179402 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  795. [795]

    Cristofanilli M, Turner NC, Bondarenko I et al.. “Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.” The Lancet. Oncology (2016). PMID: 26947331 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  796. [796]

    Oliveira M, Rugo HS, Howell SJ et al.. “Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.” The Lancet. Oncology (2024). PMID: 39214106 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  797. [797]

    Toi M, Imoto S, Ishida T et al.. “Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2021). PMID: 33387497 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  798. [798]

    Turner NC, Oliveira M, Howell SJ et al.. “Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.” The New England journal of medicine (2023). PMID: 37256976 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment
  799. [799]

    Modi S, Jacot W, Yamashita T et al.. “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.” The New England journal of medicine (2022). PMID: 35665782 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment
  800. [800]

    Bardia A, Hu X, Dent R et al.. “Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.” The New England journal of medicine (2024). PMID: 39282896 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  801. [801]

    Slamon D, Lipatov O, Nowecki Z et al.. “Ribociclib plus Endocrine Therapy in Early Breast Cancer.” The New England journal of medicine (2024). PMID: 38507751 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment
  802. [802]

    Masuda N, Lee SJ, Ohtani S et al.. “Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.” The New England journal of medicine (2017). PMID: 28564564 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  803. [803]

    von Minckwitz G, Huang CS, Mano MS et al.. “Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.” The New England journal of medicine (2018). PMID: 30516102 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  804. [804]

    Verma S, Miles D, Gianni L et al.. “Trastuzumab emtansine for HER2-positive advanced breast cancer.” The New England journal of medicine (2012). PMID: 23020162 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  805. [805]

    Modi S, Saura C, Yamashita T et al.. “Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.” The New England journal of medicine (2019). PMID: 31825192 ↗

    L4RCTCited in: Molecular Diagnostics and Biomarkers
  806. [806]

    André F, Ciruelos EM, Juric D et al.. “Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33246021 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  807. [807]

    Curigliano G, Mueller V, Borges V et al.. “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34954044 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  808. [808]

    Gambardella V, Accordino MK, Bedard PL et al.. “Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).” ESMO open (2025). PMID: 40513140 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Special Populations
  809. [809]

    Tan AR, Im SA, Mattar A et al.. “Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.” The Lancet. Oncology (2020). PMID: 33357420 ↗

    L1TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, Prognosis and Prognostic Factors
  810. [810]

    Hughes KS, Schnaper LA, Bellon JR et al.. “Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23690420 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, Special Populations
  811. [811]

    Sledge GW, Toi M, Neven P et al.. “The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.” JAMA oncology (2020). PMID: 31563959 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  812. [812]

    Wortelboer N, van Ommen-Nijhof A, Konings IR et al.. “Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial.” JAMA oncology (2026). PMID: 41712229 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  813. [813]

    Martin M, Hegg R, Kim SB et al.. “Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.” JAMA oncology (2022). PMID: 35653145 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors
  814. [814]

    van der Voort A, van Ramshorst MS, van Werkhoven ED et al.. “Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.” JAMA oncology (2021). PMID: 34014249 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  815. [815]

    Munzone E, Regan MM, Cinieri S et al.. “Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.” JAMA oncology (2023). PMID: 37440239 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Special Populations
  816. [816]

    Shao Z, Pang D, Yang H et al.. “Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.” JAMA oncology (2020). PMID: 31647503 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers
  817. [817]

    O'Leary B, Cutts RJ, Liu Y et al.. “The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.” Cancer discovery (2018). PMID: 30206110 ↗

    L3RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors
  818. [818]

    Pusztai L, Yau C, Wolf DM et al.. “Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.” Cancer cell (2021). PMID: 34143979 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  819. [819]

    Fan L, Zhang WJ, Li HP et al.. “Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.” Cancer cell (2025). PMID: 41349543 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  820. [820]

    Schettini F, Nucera S, Pascual T et al.. “Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.” Cancer treatment reviews (2024). PMID: 39709655 ↗

    L1SR_OBSCited in: Molecular Diagnostics and Biomarkers
  821. [821]

    de Almeida LFC, Leite LF, Cappellaro AP et al.. “Sequencing antibody-drug conjugates in metastatic breast cancer: A systematic review.” Cancer treatment reviews (2025). PMID: 41401644 ↗

    L5SR_OBSCited in: Molecular Diagnostics and Biomarkers
  822. [822]

    Yang Z, Meng J, Mei X et al.. “Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 Trial.” JAMA oncology (2024). PMID: 38175627 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  823. [823]

    Tsurutani J, Iwata H, Krop I et al.. “Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.” Cancer discovery (2020). PMID: 32213540 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Special Populations
  824. [824]

    Filho OM, Viale G, Stein S et al.. “Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.” Cancer discovery (2021). PMID: 33941592 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  825. [825]

    Ma D, Dai LJ, Wu XR et al.. “Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer.” Cancer cell (2025). PMID: 40215979 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  826. [826]

    Lu YS, Im SA, Colleoni M et al.. “Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 34965945 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  827. [827]

    Lin NU, Murthy RK, Abramson V et al.. “Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.” JAMA oncology (2023). PMID: 36454580 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  828. [828]

    O'Regan RM, Zhang Y, Fleming GF et al.. “Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.” JAMA oncology (2024). PMID: 39145953 ↗

    L3RCTCited in: Molecular Diagnostics and Biomarkers, Staging
  829. [829]

    Ademuyiwa FO, Ma CX, Weilbaecher K et al.. “Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40116350 ↗

    L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, Prognosis and Prognostic Factors
  830. [830]

    Arpino G, de la Haba Rodríguez J, Ferrero JM et al.. “Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36716289 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  831. [831]

    Masuda N, Saji S, Kojima Y et al.. “Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.” Breast cancer research and treatment (2026). PMID: 42420599 ↗

    L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  832. [832]

    Peiffer DS, Maloney C, Chen N. “What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer?” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 42425154 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview
  833. [833]

    Keenan TE, Tolaney SM. “Role of Immunotherapy in Triple-Negative Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32259782 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  834. [834]

    Telli ML, Witteles RM. “Trastuzumab-related cardiac dysfunction.” Journal of the National Comprehensive Cancer Network : JNCCN (2011). PMID: 21310845 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview
  835. [835]

    Santa-Maria CA, Nanda R. “Immune Checkpoint Inhibitor Therapy in Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30323094 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  836. [836]

    Spring LM, Bar Y, Isakoff SJ. “The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35714678 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  837. [837]

    Schwartzberg LS. “Use of Biomarkers and Multigene Assays in Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28515241 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers, Staging
  838. [838]

    Stabellini N, Cao L, Towe CW et al.. “Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37856198 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  839. [839]

    Kwon JS, Pansegrau G, Nourmoussavi M et al.. “Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28784863 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  840. [840]

    Eroglu Z, Fielder O, Somlo G. “Analysis of circulating tumor cells in breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23946176 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  841. [841]

    Yao H, Zhao R, Lai X et al.. “A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody-drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours.” EBioMedicine (2026). PMID: 42349255 ↗

    L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
  842. [842]

    Balaha M, Aldosari SA, Alamer AA et al.. “Tissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies.” Oncology research (2026). PMID: 42358834 ↗

    L1SR_OBSCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  843. [843]

    Goldhirsch A, Winer EP, Coates AS et al.. “Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23917950 ↗

    L1OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  844. [844]

    Magbanua MJM, Swigart LB, Wu HT et al.. “Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33232761 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  845. [845]

    Provenzano L, Dieci MV, Curigliano G et al.. “Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40204155 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers
  846. [846]

    Rastogi P, O'Shaughnessy J, Martin M et al.. “Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38194616 ↗

    L1OTHERCited in: Molecular Diagnostics and Biomarkers
  847. [847]

    Lin J, Xu H, Zhou Y et al.. “Prognostic significance of ctDNA mutations in advanced HER2-positive breast cancer treated with targeted therapy: A meta-analysis.” Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2026). PMID: 42345502 ↗

    L1SR_OBSCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  848. [848]

    Cantini L, Trapani D, Guidi L et al.. “Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.” Cancer treatment reviews (2023). PMID: 38141462 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview
  849. [849]

    Boscolo Bielo L, Trapani D, Nicolò E et al.. “The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.” Cancer treatment reviews (2024). PMID: 38772169 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview
  850. [850]

    von Arx C, De Placido P, Caltavituro A et al.. “The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.” Cancer treatment reviews (2022). PMID: 36587473 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  851. [851]

    Berton Giachetti PPM, Carnevale Schianca A, Trapani D et al.. “Current controversies in the use of Oncotype DX in early breast cancer.” Cancer treatment reviews (2025). PMID: 40048856 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  852. [852]

    Buonaiuto R, Botticelli A, Criscitiello C et al.. “Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression.” Cancer treatment reviews (2025). PMID: 40450825 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview
  853. [853]

    Sahin TK, Rizzo A, Guven DC et al.. “Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer.” Cancer treatment reviews (2025). PMID: 40121890 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  854. [854]

    Tray N, Taff J, Adams S. “Therapeutic landscape of metaplastic breast cancer.” Cancer treatment reviews (2019). PMID: 31491663 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
  855. [855]

    Dieci MV, Miglietta F, Griguolo G et al.. “Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors.” Cancer treatment reviews (2020). PMID: 32622272 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  856. [856]

    Pondé N, Brandão M, El-Hachem G et al.. “Treatment of advanced HER2-positive breast cancer: 2018 and beyond.” Cancer treatment reviews (2018). PMID: 29751334 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  857. [857]

    Tolaney SM, Punie K, Carey LA et al.. “Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States.” ESMO open (2024). PMID: 39241499 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
  858. [858]

    Llombart-Cussac A, Pérez-García JM, Bellet M et al.. “Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.” ESMO open (2025). PMID: 40532361 ↗

    L1OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
  859. [859]

    Tarantino P, Lee D, Foldi J et al.. “Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.” ESMO open (2025). PMID: 40532362 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations
  860. [860]

    Tolaney SM, Tung N, Wolff AC et al.. “HER2DX genomic test in early-stage HER2-positive breast cancer.” ESMO open (2024). PMID: 39710442 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
  861. [861]

    Rugo HS, Layman RM, Lynce F et al.. “Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice.” ESMO open (2025). PMID: 40896879 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  862. [862]

    Schlam I, Loi S, Salgado R et al.. “Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges.” ESMO open (2025). PMID: 39826475 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  863. [863]

    Yerushalmi R, Woods R, Ravdin PM et al.. “Ki67 in breast cancer: prognostic and predictive potential.” The Lancet. Oncology (2010). PMID: 20152769 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  864. [864]

    Yau C, Osdoit M, van der Noordaa M et al.. “Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.” The Lancet. Oncology (2021). PMID: 34902335 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  865. [865]

    Foulkes WD, Smith IE, Reis-Filho JS. “Triple-negative breast cancer.” The New England journal of medicine (2010). PMID: 21067385 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  866. [866]

    Vela-Ruiz JM, Morante Z, Ferreyra Y et al.. “Plasma cytokine profiles in breast cancer patients and their association with therapeutic response in Peru: a prospective cohort study.” Frontiers in immunology (2026). PMID: 42344913 ↗

    L2COHORTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  867. [867]

    Zheng Y, Chen Y, Lin W et al.. “Association between tumor genomic mutations and the risk of PD-1 inhibitor-induced hypophysitis: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42339089 ↗

    L2COHORTCited in: Molecular Diagnostics and Biomarkers
  868. [868]

    Garrido-Castro AC, Lin NU, Polyak K. “Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.” Cancer discovery (2019). PMID: 30679171 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  869. [869]

    Song KW, Edgar KA, Hanan EJ et al.. “RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy.” Cancer discovery (2021). PMID: 34544753 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  870. [870]

    Wilding B, Woelflingseder L, Baum A et al.. “Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.” Cancer discovery (2025). PMID: 39248702 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  871. [871]

    Chen W, Gupta A, Mai N et al.. “Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding.” Cancer discovery (2026). PMID: 41212147 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  872. [872]

    Chang CA, Jen J, Jiang S et al.. “Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.” Cancer discovery (2022). PMID: 34911733 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  873. [873]

    Dashzeveg NK, Jia Y, Zhang Y et al.. “Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer.” Cancer discovery (2023). PMID: 37272843 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  874. [874]

    Alam R, Reva A, Edwards DG et al.. “Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer.” Cancer discovery (2025). PMID: 39835789 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  875. [875]

    Jerusalem G, Park YH, Yamashita T et al.. “Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.” Cancer discovery (2022). PMID: 36255231 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
  876. [876]

    . “T-DXd Keeps Shining in Breast Cancer.” Cancer discovery (2023). PMID: 36484540 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  877. [877]

    Jiang YZ, Ma D, Suo C et al.. “Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.” Cancer cell (2019). PMID: 30853353 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  878. [878]

    Razavi P, Chang MT, Xu G et al.. “The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.” Cancer cell (2018). PMID: 30205045 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
  879. [879]

    Gan S, Macalinao DG, Shahoei SH et al.. “Distinct tumor architectures and microenvironments for the initiation of breast cancer metastasis in the brain.” Cancer cell (2024). PMID: 39270646 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  880. [880]

    Magbanua MJM, Brown Swigart L, Ahmed Z et al.. “Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.” Cancer cell (2023). PMID: 37146605 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  881. [881]

    Wolf DM, Yau C, Wulfkuhle J et al.. “Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.” Cancer cell (2022). PMID: 35623341 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  882. [882]

    Meyer L, Jackson HW, Eling N et al.. “A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture.” Cancer cell (2025). PMID: 40680742 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  883. [883]

    Li JY, Perry SR, Muniz-Medina V et al.. “A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.” Cancer cell (2016). PMID: 26766593 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  884. [884]

    Jassowicz L, Feng F, Warta R et al.. “Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes.” Cancer cell (2026). PMID: 42049023 ↗

    L4OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  885. [885]

    Goel S, Wang Q, Watt AC et al.. “Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.” Cancer cell (2016). PMID: 26977878 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  886. [886]

    Shen M, Jiang YZ, Wei Y et al.. “Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.” Cancer cell (2019). PMID: 30612941 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  887. [887]

    Tan Y, Ye Y, Zhao W et al.. “Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.” Cancer biology & therapy (2026). PMID: 42337391 ↗

    L2COHORTCited in: Molecular Diagnostics and Biomarkers
  888. [888]

    Elliott MJ, Howarth K, Main S et al.. “Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39785866 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
  889. [889]

    Coombes RC, Page K, Salari R et al.. “Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30992300 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  890. [890]

    Kabraji S, Ni J, Sammons S et al.. “Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36074155 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  891. [891]

    Lin CA, Chica-Parrado MR, Unni N et al.. “ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39992682 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  892. [892]

    Lloyd MR, Weipert CM, Ali A et al.. “Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41201834 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  893. [893]

    Meric-Bernstam F, Yuca E, Evans KW et al.. “Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39585341 ↗

    L5OTHERCited in: Molecular Diagnostics and Biomarkers
  894. [894]

    Rugo HS, Kaklamani V, McArthur H et al.. “Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41235919 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  895. [895]

    Emens LA. “Breast Cancer Immunotherapy: Facts and Hopes.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28801472 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  896. [896]

    Priedigkeit N, Harrison B, Shue R et al.. “Clinicogenomic Characterization of Inflammatory Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40378057 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
  897. [897]

    Martins-Branco D, Lobo-Martins S, Aftimos P et al.. “EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.” Breast cancer research and treatment (2026). PMID: 42429895 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
  898. [898]

    Di Cosimo S, Appierto V, Reduzzi C et al.. “Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps.” Cancer (2026). PMID: 42421646 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview
  899. [899]

    Rafii S, Al-Shamsi HO, Brufsky A. “SERENA-6 and the regulatory limits of radiologic progression in modern oncology.” Breast cancer research and treatment (2026). PMID: 42418030 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  900. [900]

    Gradishar WJ, Moran MS, Abraham J et al.. “Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 42425164 ↗

    L1GUIDELINECited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  901. [901]

    Gradishar WJ, Moran MS, Abraham J et al.. “NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41213254 ↗

    L1GUIDELINECited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  902. [902]

    Gradishar WJ, Anderson BO, Balassanian R et al.. “Breast Cancer Version 2.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25870381 ↗

    L1GUIDELINECited in: Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors
  903. [903]

    Gradishar WJ, Anderson BO, Balassanian R et al.. “Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 26957618 ↗

    L1GUIDELINECited in: Staging, History and Evolution of Treatment
  904. [904]

    Coyle C, Cafferty FH, Vale C et al.. “Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27681864 ↗

    L1SR_OBSCited in: Staging
  905. [905]

    Yang SH, Yang KH, Li YP et al.. “Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 18187486 ↗

    L1SR_MA_RCTCited in: Staging
  906. [906]

    Pusztai L, Denkert C, O'Shaughnessy J et al.. “Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38369015 ↗

    L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Special Populations
  907. [907]

    Gnant M, Dueck AC, Frantal S et al.. “Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34874182 ↗

    L1RCTCited in: Staging, Management Overview, Prognosis and Prognostic Factors
  908. [908]

    Jones SE, Savin MA, Holmes FA et al.. “Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 17135639 ↗

    L1RCTCited in: Staging
  909. [909]

    Tolaney SM, Tayob N, Dang C et al.. “Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34077270 ↗

    L1RCTCited in: Staging
  910. [910]

    Chen X, Huang J, Shi H et al.. “Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 41365333 ↗

    L1RCTCited in: Staging
  911. [911]

    Li JJ, Zhang WJ, Zeng XH et al.. “Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 41289548 ↗

    L1RCTCited in: Staging
  912. [912]

    Schettini F, Pascual T, Conte B et al.. “HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2020). PMID: 32000054 ↗

    L1SR_OBSCited in: Staging
  913. [913]

    Al-Mubarak M, Sacher AG, Ocana A et al.. “Fulvestrant for advanced breast cancer: a meta-analysis.” Cancer treatment reviews (2013). PMID: 23764179 ↗

    L1SR_OBSCited in: Staging
  914. [914]

    Saleh RR, Nadler MB, Desnoyers A et al.. “Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis.” Cancer treatment reviews (2021). PMID: 34530283 ↗

    L1SR_OBSCited in: Staging
  915. [915]

    Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D et al.. “Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.” Cancer treatment reviews (2017). PMID: 29126017 ↗

    L1SR_OBSCited in: Staging
  916. [916]

    Bramati A, Girelli S, Torri V et al.. “Efficacy of biological agents in metastatic triple-negative breast cancer.” Cancer treatment reviews (2014). PMID: 24529896 ↗

    L1SR_OBSCited in: Staging, Special Populations
  917. [917]

    Villacampa G, Pascual T, Tarantino P et al.. “HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.” The Lancet. Oncology (2025). PMID: 40675165 ↗

    L1SR_OBSCited in: Staging
  918. [918]

    Zelnak AB, O'Regan RM. “Optimizing Endocrine Therapy for Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26285250 ↗

    L5REVIEW_NARRATIVECited in: Staging, Prognosis and Prognostic Factors
  919. [919]

    Kuemmel S, Jung KH, Andrade L et al.. “Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.” ESMO open (2025). PMID: 41297162 ↗

    L4RCTCited in: Staging
  920. [920]

    Tripathy D, Im SA, Colleoni M et al.. “Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.” The Lancet. Oncology (2018). PMID: 29804902 ↗

    L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  921. [921]

    Chen XC, Jiao DC, Qiao JH et al.. “De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.” The Lancet. Oncology (2024). PMID: 39612919 ↗

    L1RCTCited in: Staging
  922. [922]

    Martin M, Holmes FA, Ejlertsen B et al.. “Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Oncology (2017). PMID: 29146401 ↗

    L1RCTCited in: Staging
  923. [923]

    Schmid P, Cortes J, Dent R et al.. “Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.” The New England journal of medicine (2024). PMID: 39282906 ↗

    L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  924. [924]

    Kunkler IH, Russell NS, Anderson N et al.. “Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.” The New England journal of medicine (2025). PMID: 41191939 ↗

    L1RCTCited in: Staging
  925. [925]

    Hortobagyi GN, Stemmer SM, Burris HA et al.. “Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.” The New England journal of medicine (2016). PMID: 27717303 ↗

    L1RCTCited in: Staging
  926. [926]

    von Minckwitz G, Eidtmann H, Rezai M et al.. “Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.” The New England journal of medicine (2012). PMID: 22276820 ↗

    L1RCTCited in: Staging
  927. [927]

    Swain SM, Jeong JH, Geyer CE et al.. “Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.” The New England journal of medicine (2010). PMID: 20519679 ↗

    L1RCTCited in: Staging
  928. [928]

    Jhaveri KL, Accordino MK, Bedard PL et al.. “Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39236276 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  929. [929]

    Munhoz RR, Pereira AA, Sasse AD et al.. “Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.” JAMA oncology (2016). PMID: 26426573 ↗

    L1SR_OBSCited in: Staging
  930. [930]

    Radovich M, Jiang G, Hancock BA et al.. “Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.” JAMA oncology (2020). PMID: 32644110 ↗

    L2RCTCited in: Staging, Prognosis and Prognostic Factors
  931. [931]

    Nanda R, Liu MC, Yau C et al.. “Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.” JAMA oncology (2020). PMID: 32053137 ↗

    L1RCTCited in: Staging, History and Evolution of Treatment
  932. [932]

    Ligibel JA, Ballman KV, McCall L et al.. “Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) Trial.” JAMA oncology (2025). PMID: 40839373 ↗

    L1RCTCited in: Staging
  933. [933]

    Rios-Hoyo A, Dai J, Noel T et al.. “Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer.” ESMO open (2025). PMID: 40107153 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  934. [934]

    Kuerer HM, Smith BD, Krishnamurthy S et al.. “Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology (2022). PMID: 36306810 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  935. [935]

    Oakman C, Sapino A, Marchiò C et al.. “Chemotherapy with or without trastuzumab.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20943603 ↗

    L5REVIEW_NARRATIVECited in: Staging
  936. [936]

    Azambuja E, Durbecq V, Rosa DD et al.. “HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17872901 ↗

    L5REVIEW_NARRATIVECited in: Staging
  937. [937]

    Aapro M, Andre F, Blackwell K et al.. “Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24667713 ↗

    L5REVIEW_NARRATIVECited in: Staging
  938. [938]

    Banys-Paluchowski M, Solbach C, Kühn T et al.. “AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42173036 ↗

    L1GUIDELINECited in: Staging
  939. [939]

    Sharma P, Kimler BF, O'Dea A et al.. “Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 33208340 ↗

    L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment
  940. [940]

    Llombart-Cussac A, Pérez-García J, Brasó-Maristany F et al.. “HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38995291 ↗

    L1RCTCited in: Staging
  941. [941]

    de Groot AF, Cohen D, Heijns JB et al.. “Ribociclib-Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01).” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40495424 ↗

    L1RCTCited in: Staging
  942. [942]

    Martín M, Guerrero-Zotano ÁL, Pérez-López ME et al.. “Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41385615 ↗

    L1RCTCited in: Staging
  943. [943]

    Fasching PA, Slamon D, Nowecki Z et al.. “Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40019493 ↗

    L1RCTCited in: Staging
  944. [944]

    Kim J, Kim J, Seo KH et al.. “Survival outcomes of young-age female patients with early breast cancer: an international multicenter cohort study.” ESMO open (2024). PMID: 39413678 ↗

    L2COHORTCited in: Staging
  945. [945]

    Joko-Fru WY, Griesel M, Mezger NCS et al.. “Breast Cancer Diagnostics, Therapy, and Outcomes in Sub-Saharan Africa: A Population-Based Registry Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 34965508 ↗

    L2OTHERCited in: Staging
  946. [946]

    Telli ML, Timms KM, Reid J et al.. “Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26957554 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  947. [947]

    Corti C, Binboğa Kurt B, Koca B et al.. “Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy.” Cancer treatment reviews (2024). PMID: 39571402 ↗

    L5REVIEW_NARRATIVECited in: Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors
  948. [948]

    Yang SX, Polley E, Lipkowitz S. “New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.” Cancer treatment reviews (2016). PMID: 26995633 ↗

    L5REVIEW_NARRATIVECited in: Staging
  949. [949]

    Criscitiello C, Esposito A, Trapani D et al.. “Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer.” Cancer treatment reviews (2016). PMID: 27744144 ↗

    L5REVIEW_NARRATIVECited in: Staging
  950. [950]

    Megerdichian C, Olimpiadi Y, Hurvitz SA. “nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.” Cancer treatment reviews (2014). PMID: 24560997 ↗

    L5REVIEW_NARRATIVECited in: Staging, Special Populations
  951. [951]

    Shi M, Guo N. “MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer.” Cancer treatment reviews (2009). PMID: 19171434 ↗

    L5REVIEW_NARRATIVECited in: Staging
  952. [952]

    Marra A, Viale G, Pileri SA et al.. “Breast implant-associated anaplastic large cell lymphoma: A comprehensive review.” Cancer treatment reviews (2020). PMID: 31958739 ↗

    L5REVIEW_NARRATIVECited in: Staging
  953. [953]

    Carbognin L, Sperduti I, Nortilli R et al.. “Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.” Cancer treatment reviews (2015). PMID: 25683304 ↗

    L1REVIEW_NARRATIVECited in: Staging
  954. [954]

    Speers C, Pierce LJ. “Postoperative Radiotherapy After Breast-Conserving Surgery for Early-Stage Breast Cancer: A Review.” JAMA oncology (2016). PMID: 27243924 ↗

    L5REVIEW_NARRATIVECited in: Staging
  955. [955]

    Goldhirsch A, Wood WC, Coates AS et al.. “Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21709140 ↗

    L5OTHERCited in: Staging
  956. [956]

    Kaidar-Person O, Weltens CG, Fortpied C et al.. “Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.” The Lancet. Oncology (2026). PMID: 42372743 ↗

    L1RCTCited in: Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  957. [957]

    Kaidar-Person O, Weltens CG, Fortpied C et al.. “Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer.” CA: a cancer journal for clinicians (2026). PMID: 42141924 ↗

    L1RCTCited in: Staging
  958. [958]

    Brunt AM, Cafferty FH, Kirby AM et al.. “Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy.” The Lancet. Oncology (2026). PMID: 42134381 ↗

    L1RCTCited in: Staging
  959. [959]

    Fall AD, Veses V, Sheth CC. “Stage at Diagnosis and Molecular Subtype Distribution of Breast Cancer in Sub-Saharan Africa: A Systematic Review.” Cancer reports (Hoboken, N.J.) (2026). PMID: 42266142 ↗

    L2SR_OBSCited in: Staging
  960. [960]

    Liedtke C, Mazouni C, Hess KR et al.. “Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18250347 ↗

    L2OTHERCited in: Staging
  961. [961]

    Hunter NB, Parsons HA, Cope L et al.. “The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41805422 ↗

    L2OTHERCited in: Staging
  962. [962]

    Caudle AS, Yang WT, Krishnamurthy S et al.. “Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26811528 ↗

    L2OTHERCited in: Staging
  963. [963]

    Montagna G, Laws A, Ferrucci M et al.. “Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39509672 ↗

    L3OTHERCited in: Staging
  964. [964]

    Ahmed S, Mannala S, Mondal P et al.. “Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.” Breast cancer research and treatment (2026). PMID: 42360361 ↗

    L2TRIAL_NONRANDOMCited in: Staging, Prognosis and Prognostic Factors
  965. [965]

    Breidenbach C, Hage AM, Schellack SK et al.. “Providers' perspectives on implementing alert-based patient-reported outcome monitoring for stage IV breast cancer.” Journal of patient-reported outcomes (2026). PMID: 42236639 ↗

    L5RCTCited in: Staging
  966. [966]

    Elliott MJ, Kim J, Dou A et al.. “Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer.” ESMO open (2025). PMID: 40472659 ↗

    L3OTHERCited in: Staging
  967. [967]

    de Graaf M, Gielen RCAM, Balduzzi S et al.. “Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study.” ESMO open (2025). PMID: 41352286 ↗

    L3OTHERCited in: Staging
  968. [968]

    Corti C, Chu X, Exman P et al.. “Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study.” ESMO open (2025). PMID: 40714511 ↗

    L2OTHERCited in: Staging
  969. [969]

    Raghavendra AS, Zakon DB, Jin Q et al.. “Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆.” ESMO open (2024). PMID: 39500139 ↗

    L3OTHERCited in: Staging
  970. [970]

    Seitz K, Goossens C, Huebner H et al.. “Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer.” ESMO open (2024). PMID: 39461262 ↗

    L3OTHERCited in: Staging
  971. [971]

    Borea R, Blondeaux E, Carmisciano L et al.. “Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials.” ESMO open (2026). PMID: 41499989 ↗

    L2OTHERCited in: Staging
  972. [972]

    Yang Z, Ni P, Wang Y et al.. “Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study.” Cancer medicine (2026). PMID: 42204769 ↗

    L3COHORTCited in: Staging
  973. [973]

    Geurts VCM, Balduzzi S, Steenbruggen TG et al.. “Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.” JAMA oncology (2024). PMID: 38935352 ↗

    L3OTHERCited in: Staging
  974. [974]

    Hoskins KF, Calip GS, Huang HC et al.. “Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast Cancer.” JAMA oncology (2023). PMID: 36795405 ↗

    L3OTHERCited in: Staging
  975. [975]

    . “MammaPrint Reduces Breast Cancer Overtreatment.” Cancer discovery (2016). PMID: 27095361 ↗

    L5OTHERCited in: Staging, Prognosis and Prognostic Factors
  976. [976]

    Wang H, Yu C, Gao X et al.. “The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells.” Cancer cell (2015). PMID: 25600338 ↗

    L5OTHERCited in: Staging
  977. [977]

    Wang L, Deng H, Fang X et al.. “Clinical and Pathological Characteristics and Prognosis of Breast Cancer During Pregnancy and Postpartum: A Multicenter Retrospective Study.” Cancer reports (Hoboken, N.J.) (2026). PMID: 42243585 ↗

    L3COHORTCited in: Staging
  978. [978]

    Maitland ML, Sachdev JC, Sharma MR et al.. “First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34083232 ↗

    L4OTHERCited in: Staging
  979. [979]

    Licata L, Mariani M, Viale G et al.. “Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40689866 ↗

    L2OTHERCited in: Staging, Management Overview
  980. [980]

    Garrido-Castro AC, Spurr LF, Hughes ME et al.. “Genomic Characterization of de novo Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 33293374 ↗

    L2OTHERCited in: Staging
  981. [981]

    Barajas-Garcia MZ, Hernández-Sánchez EN, Ayala-Andrade MM et al.. “Challenges and outcomes of breast reconstruction in advanced-stage breast cancer: a comprehensive review.” Cirugia y cirujanos (2026). PMID: 42184403 ↗

    L5SR_OBSCited in: Staging
  982. [982]

    Gradishar WJ, Moran MS, Abraham J et al.. “Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39019058 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
  983. [983]

    Gradishar WJ, Moran MS, Abraham J et al.. “Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35714673 ↗

    L1GUIDELINECited in: Management Overview
  984. [984]

    Gradishar WJ, Anderson BO, Blair SL et al.. “Breast cancer version 3.2014.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24717572 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
  985. [985]

    Salgado R, Denkert C, Demaria S et al.. “The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25214542 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
  986. [986]

    Mosele MF, Westphalen CB, Stenzinger A et al.. “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38834388 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
  987. [987]

    Jimenez RB, Abdou Y, Anderson P et al.. “Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40955654 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
  988. [988]

    Burstein HJ, Lacchetti C, Anderson H et al.. “Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30452337 ↗

    L1GUIDELINECited in: Management Overview
  989. [989]

    Pagani O, Walley BA, Fleming GF et al.. “Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36521078 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors
  990. [990]

    Francis PA, Fleming GF, Láng I et al.. “Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36493334 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
  991. [991]

    Piccart M, Procter M, Fumagalli D et al.. “Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33539215 ↗

    L1RCTCited in: Management Overview
  992. [992]

    Loibl S, Jassem J, Sonnenblick A et al.. “Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39259927 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  993. [993]

    Behroozian T, Bonomo P, Patel P et al.. “Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations.” The Lancet. Oncology (2023). PMID: 36990615 ↗

    L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
  994. [994]

    Rugo HS, Oliveira M, Howell SJ et al.. “Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.” ESMO open (2024). PMID: 39241495 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
  995. [995]

    Bardia A, Hurvitz SA, Tolaney SM et al.. “Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.” The New England journal of medicine (2021). PMID: 33882206 ↗

    L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
  996. [996]

    Eisen A, Somerfield MR, Accordino MK et al.. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35041467 ↗

    L1SR_OBSCited in: Management Overview
  997. [997]

    Asleh K, Lluch A, Goytain A et al.. “Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36346687 ↗

    L3RCTCited in: Management Overview, History and Evolution of Treatment
  998. [998]

    Sharma P, Stecklein SR, Yoder R et al.. “Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.” JAMA oncology (2024). PMID: 37991778 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors
  999. [999]

    Gentry AL, Sereika SM, Erickson KI et al.. “The relationship of neighborhood socioeconomic disadvantage and pretreatment cancer-related cognitive impairment in women with breast cancer: A post hoc analysis of a randomized controlled trial.” Cancer (2026). PMID: 42421660 ↗

    L3RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
  1000. [1000]

    Dushkin H, Cristofanilli M. “Inflammatory breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2011). PMID: 21310844 ↗

    L5REVIEW_NARRATIVECited in: Management Overview

Revision History

All updates applied to this page

Loading revisions…